WO1999026635A1 - Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof - Google Patents

Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof Download PDF

Info

Publication number
WO1999026635A1
WO1999026635A1 PCT/CN1998/000277 CN9800277W WO9926635A1 WO 1999026635 A1 WO1999026635 A1 WO 1999026635A1 CN 9800277 W CN9800277 W CN 9800277W WO 9926635 A1 WO9926635 A1 WO 9926635A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaginal
gram
medicament
positive
growth
Prior art date
Application number
PCT/CN1998/000277
Other languages
French (fr)
Chinese (zh)
Inventor
Zhongming Zeng
Original Assignee
Zhongming Zeng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongming Zeng filed Critical Zhongming Zeng
Priority to DE69831609T priority Critical patent/DE69831609T2/en
Priority to AU12230/99A priority patent/AU1223099A/en
Priority to AT98955312T priority patent/ATE304362T1/en
Priority to EP98955312A priority patent/EP1072268B1/en
Publication of WO1999026635A1 publication Critical patent/WO1999026635A1/en
Priority to US09/577,858 priority patent/US6632796B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Abstract

The present invention relates to a pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina which comprises sucrose and/or maltose, to the use of sucrose and/or maltose in preparing the pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina, in particular to a method for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina, treating the reduction of gram-positive bacilli and the lowness of acidity in vagina as well as the vaginitis and the disturbance of vaginal bacterioflora accompanying the reduction of gram-positive bacilli, especially bacterial vaginal disease, which applies sucrose and/or maltose.

Description

剌激阴道革兰氏阳性杆菌生长、 增强  Stimulates growth and enhancement of vaginal Gram-positive bacilli
阴道酸度的药剂和其用途 发明领域: 本发明涉及以糖为活性成分的刺激阴道革兰氏阳性杆菌生长、 增 强阴道酸度的药剂,涉及特定的糖在制备刺激阴道革兰氏阳性杆菌生 长、增强阴道酸度的药剂中的应用,还特别涉及一种刺激阴道革兰氏 阳性杆菌生长、 增强阴道酸度、 治疗阴道革兰氏阳性杆菌减少、 阴道 酸度减弱、 以及伴有革兰氏阳性杆菌减少的阴道炎和阴道菌群失调、 特别是细菌性阴道病的方法。 背景技术的描述: 女性阴道的酸度是阴道抵抗病菌感染的重要机制之一, 对于维护 阴道健康具有十分重要的意义。 具有产酸、 耐酸能力的乳酸杆菌 Vaginal acidity medicament and use thereof Field of the invention: The present invention relates to a medicament for stimulating the growth of vaginal gram-positive bacilli and enhancing vaginal acidity by using sugar as an active ingredient, and relates to a specific sugar prepared for stimulating vaginal gram-positive bacillus growth and enhancing The application in vaginal acidity medicaments also specifically relates to a method for stimulating the growth of vaginal gram-positive bacilli, enhancing vaginal acidity, treating a decrease in vaginal gram-positive bacilli, weakening vaginal acidity, and a vagina with a decrease in gram-positive bacilli Methods for inflammation and vaginal flora disorders, especially bacterial vaginosis. Description of the Background Art: The acidity of a woman's vagina is one of the important mechanisms for vaginal resistance to bacterial infections, and is of great significance for maintaining vaginal health. Lactobacillus with acid-producing and acid-resistant ability
( Lactobacillus )等革兰氏阳性杆菌在阴道正常酸度的维持中发挥 着重要作用, 使阴道正常 pH值保持在 4.0-4.6范围内, 它们是阴道 的生理性菌群。 而革兰氏阴性杆菌、 阴性球菌、 阳性球菌等在健康阴 道中的量则相对较少或极少。 Gram-positive bacilli such as Lactobacillus play an important role in maintaining the normal acidity of the vagina, keeping the normal pH of the vagina in the range of 4.0-4.6, and they are the physiological flora of the vagina. The amount of Gram-negative bacilli, negative cocci, and positive cocci in healthy vagina is relatively small or very small.
当阴道中阳性杵菌减少或消失、 阴道 pH值升高时, 就会出现多 种革兰氏阴性杆菌、 阴性球菌及阳性球菌等异常生长增多, 形成阴道 菌群失调, 可对人体产生相应危害并引起一系列病征。其中以细菌性 阴道病( Bacterial Vaginosis , BV )最为典型, 其菌群改变特征是 阴道内乳酸杆菌等革兰氏阳性杵菌的数量减少甚至消失,伴有阴道酸 度减弱、 pH值升高( pH>4.6 ) , 而加德纳氏菌、 类杆菌、 动弯杆 菌等阴性杆菌和韦荣氏球菌等阴性球菌、以及链球菌等阳性球菌等异 常细菌大量生长增多, 引起白带臭味、 外阴瘙痒等一系列病征, 并可 导致胎儿宫内发育迟緩 ( IUGR ) [1]、 早产 ( PTL )、 胎膜早破 ( PROM ) [2】、 流产以及产科感染, 绒膜羊膜炎、 产后子宫内膜炎、 子宫切除术后阴道壁蜂窝组织炎等女性上生殖道感染、泌尿系感染等 等【3】 。 阴道菌群失调的发病率很高, 是女性常见疾病, 有文献报道, 约 45%以上的妇女阴道炎由阴道菌群失调引起 [3], 美国女大学生细 菌性阴道病的发病率为 4一 15%[4], 给女性身体健康和生活质量带 来严重危害。 When the vaginal positive pestles are reduced or disappeared, and the vaginal pH value is increased, a variety of abnormal growth of Gram-negative bacilli, negative cocci and positive cocci will occur, forming a vaginal flora imbalance, which can cause corresponding harm to the human body. And cause a series of symptoms. Among them, bacterial vaginosis (Bacterial Vaginosis, BV) is the most typical. Its bacterial flora is characterized by the decrease or even disappearance of gram-positive pestles such as lactobacillus in the vagina, accompanied by weakened vaginal acidity and increased pH (pH > 4.6), and negative bacteria such as Gardnerella, Bacteroides, Campylobacter and negative cocci such as Veillonella, and positive cocci such as streptococcus increased a lot, causing leucorrhea odor, vulvar itching, etc. A series of symptoms, and Causes fetal intrauterine growth retardation (IUGR) [1], premature delivery (PTL), premature rupture of membranes (PROM) [2], abortion and obstetric infections, chorioamnionitis, postpartum endometritis, hysterectomy Vaginal wall cellulitis and other upper reproductive tract infections, urinary tract infections, etc. in women [3]. The incidence of vaginal flora disorders is very high, and it is a common disease in women. It has been reported in the literature that about 45% of women with vaginitis are caused by vaginal flora disorders [3], the incidence of bacterial vaginosis in American female college students is 41%. 15% [4], causing serious harm to women's health and quality of life.
但目前对阴道革兰氏阳性杵菌减少、 阴道酸度减弱、 以及相关的 阴道菌群失调、 阴道炎和细菌性阴道病等的治疗效果,还存在比较明 显的欠缺:  However, there are still significant deficiencies in the treatment of vaginal Gram-positive pestles, weakened vaginal acidity, and related vaginal flora disorders, vaginitis and bacterial vaginosis:
1 )抗菌药物: 即用抗菌药物抑制增多的革兰氏阴性杆菌等异常 细菌, 使用最多的药物是氯林可霉素和灭滴灵 [5 、 6], 对阴道中异 常增长的细菌有迅速和肯定的杀菌、抑菌效果。但革兰氏阳性杆菌(乳 酸杆菌)恢复不太好, 且阴道的 pH值也很难降至正常范围。  1) Antibacterial drugs: antibacterial drugs are used to inhibit the increase of abnormal bacteria such as Gram-negative bacilli. The most commonly used drugs are clindamycin and metronidazole [5, 6], which have rapid growth of abnormal bacteria in the vagina. And a positive bactericidal and bacteriostatic effect. However, Gram-positive bacilli (Lactobacillus) recover poorly, and it is difficult to lower the vaginal pH to the normal range.
2 )乳酸制剂: 细菌性阴道病患者的阴道分泌物 pH值升高。 瑞 典的研究者采用乳酸凝胶改善和恢复阴道低酸环境,可使部分患者的 阴道革兰氏阳性杵菌(乳酸杆菌)得到恢复 [7], 但有研究认为乳酸 制剂的效果不如抗菌药物 [8]。  2) Lactic acid preparation: The pH value of vaginal secretions of patients with bacterial vaginosis increases. Swedish researchers use lactic acid gel to improve and restore the vaginal low-acid environment, which can restore vaginal Gram-positive pestles (lactobacillus) in some patients [7], but some studies have suggested that lactic acid preparations are not as effective as antibacterial drugs [ 8].
3 )乳酸杵菌制剂: 阴道中的革兰氏阳性杆菌主要是乳酸杵菌。 阴道菌群失调时乳酸杆菌减少或消失, 革兰氏阴性杵菌、 阴性球菌和 革兰氏阳性球菌等增加。在阴道内直接补充乳酸杵菌, 可使部分患者 阴道中的革兰氏阳性杆菌恢复 [9】。 但疗效不够稳定, 且乳杆菌活菌 制剂的保存比较困难, 制品在储存过程中活菌数降低较快, 严重影响 制品的有效期【10]。  3) Lactobacillus lactis preparation: Gram-positive bacteria in the vagina are mainly Lactobacillus lactis. When the vaginal flora is imbalanced, lactobacillus decreases or disappears, and Gram-negative pestles, negative cocci, and gram-positive cocci increase. The supplementation of Pestridium lactis directly in the vagina can restore Gram-positive bacilli in the vagina of some patients [9]. However, the curative effect is not stable enough, and the preservation of the live lactobacillus preparation is difficult, and the number of viable bacteria decreases rapidly during storage, which seriously affects the expiration date of the product [10].
国际专利申请 WO94/02148公开了一种治疗外阴炎和外阴阴道 炎的药物组合物, 提示能在减轻症状的同时促进阴道上皮组织再生。 其活性成分部分由 7-8种物质組合而成。 该组合物含有 3.0-15.0%的 乳糖或葡萄糖。 如该申请的公开说明书第 5页 8-10行所述, 该组合 物中的乳糖或葡萄糖用作碳源。但该申请中没有提及可单独用糖作为 治疗外阴炎和阴道外阴炎的活性成分,也没有显示或暗示该组合物能 刺激阴道革兰氏阳性杆菌的生长,更没有提及任何其它种类的糖可作 为活性成分用于治疗有关阴道疾病。 另外如申请的公开说明书第 5 页 17-18行所述, 该专利申请很强调組合物的 pH值范围为 2-3.5。 International patent application WO94 / 02148 discloses a pharmaceutical composition for treating vulvitis and vulvovaginitis, suggesting that it can promote vaginal epithelial tissue regeneration while reducing symptoms. Its active ingredient is composed of 7-8 substances. The composition contains 3.0 to 15.0% of lactose or glucose. The combination is described in line 8-10 of page 5 of the publication of the application. Lactose or glucose is used as a carbon source. However, the application does not mention that sugar can be used alone as an active ingredient for treating vulvitis and vaginal vulvitis, nor does it show or suggest that the composition can stimulate the growth of vaginal Gram-positive bacilli, let alone any other kind Sugar can be used as an active ingredient in the treatment of vaginal diseases. In addition, as described in line 17-18 on page 5 of the published specification of the application, this patent application emphasizes that the pH value of the composition ranges from 2 to 3.5.
美国专利 3,860,707中公开了一种治疗滴虫性阴道炎和念珠菌阴 道炎的方法。 该方法是在阴道中施用乳果糖( Lactulose )。 该专利 中还提到乳果糖可与诸如葡萄糖、半乳糖或乳糖等载体混合给药。其 中要求治疗用的乳果糖浓度很高, 达 50%, 同时还含有 5%乳糖、 8%半乳糖等做为药物载体, 如申请的公开说明书第 1纵列 51-55行 以及第 5纵列 1-5行所述; 乳果糖用量为每次 4-10克、 每日 1-2次, 如申请公开的说明书第 4纵列 63-66行所述。但该专利的治疗方法没 有提及对细菌性阴道病等其它与念珠菌性阴道炎完全不同的阴道疾 病的治疗作用, 也没有提及低、 中浓度( 2.5-17% )、 小剂量(每日 总量 0.24-2.1克)乳果糖能刺激阴道革兰氏阳性杆菌生长、增强阴道 酸度, 也没有提及除乳果糖外任何糖的治疗作用。  U.S. Patent 3,860,707 discloses a method for treating trichomonas vaginitis and candida vulvitis. This method involves applying lactulose (Lactulose) to the vagina. The patent also mentions that lactulose can be administered in admixture with carriers such as glucose, galactose or lactose. The lactulose concentration required for treatment is very high, reaching 50%, and also contains 5% lactose, 8% galactose, etc. as a drug carrier, such as the first published column 51-55 and the fifth column As described in lines 1-5; the amount of lactulose is 4-10 grams each time, 1-2 times a day, as described in line 63-66 of the fourth column of the specification for application disclosure. However, the patent's treatment method does not mention the treatment of vaginosis and other vaginal diseases that are completely different from Candida vaginitis, nor does it mention low, medium concentration (2.5-17%), small dose (every Daily total 0.24-2.1 grams) Lactulose can stimulate the growth of vaginal Gram-positive bacilli and enhance vaginal acidity, and there is no mention of any sugar's therapeutic effect except lactulose.
欧洲专利申请 EP-A-0257007公开了一种含有乳酸和緩冲物质 及乳杵菌生长底物的药剂, 用于改变阴道微环境、使阴道中有害细菌 生长受抑制而有利于乳酸杵菌生长。该申请提到以糖原和乳糖作为生 长底物, 但如该申请的公开说明书第 6纵列 10-14行所述, 该治疗剂 的组成以乳酸为主, 乳酸与糖原或乳糖间的重量比为 20:1-500:1, 糖原或乳糖的含量仅为 0.1-0.166%。同时如该申请的公开说明书第 6 纵列 1-2行所述, 强调药剂的 pH值范围调节至 3.5-4.0很重要。 该 申请公开的体外实验结果显示出该药剂对病原菌有较强的选择性杀 菌作用, 而乳酸杆菌可在该药剂中存活较长时间。但没有任何体外或 体内实验显示该药剂能刺激乳酸杆菌生长、产酸。该申请也没有提示 单独使用乳糖或糖原、 以及任何其它糖类作为活性成分时的治疗作 用。 GB2112285A公开了一种阴道清洁洗液组合物, 其为乙酸或乳 酸加乙酸钠组成的緩冲液, 其 pH值如实施例所示为 5.71-6.2 ; 其还 含有乳杆菌营养物, 其中营养物使用了 1-2% ( W/V ) 的葡萄糖、 不饱和脂肪酸, 也泛泛地提到单糖和 /或二糖。 该药剂的主要药效作 用机制是乙酸或乳酸加乙酸钠组成的緩冲液能选择性抑制病菌而不 抑制乳酸軒菌, 如该申请的公开的第 2项和第 3项权利要求所述, 以 及如该申请公开的体外实验显示该阴道清洁洗液对多种病菌均有较 强的抑制作用, 而乳酸杆菌在该药剂中存活的时间较长。但没有任何 体外或体内实验数据显示该洗液具有刺激乳酸杵菌生长和产酸的作 用, 更没有提示单独以葡萄糖、 以及任何其它糖类为主要活性成分时 的药效作用。 另该申请错误地认为乳酸杆菌调节阴道 pH值至 5.8左 右, 如该申请的说明书第一页 20-23行所述。 The European patent application EP-A-0257007 discloses a medicament containing lactic acid and a buffer substance and a lactobacillus growth substrate, which is used to change the vaginal microenvironment, inhibit the growth of harmful bacteria in the vagina, and facilitate the growth of lactobacillus lactis. The application mentions glycogen and lactose as growth substrates, but as described in column 6-14 of column 6 of the publication of the application, the composition of the therapeutic agent is mainly lactic acid, and the relationship between lactic acid and glycogen or lactose The weight ratio is 20: 1-500: 1, and the content of glycogen or lactose is only 0.1-0.166%. At the same time, as described in column 1-2 of column 6 of the publication of the application, it is important to emphasize that the pH range of the agent is adjusted to 3.5-4.0. The results of in vitro experiments disclosed in this application show that the agent has a strong selective bactericidal effect on pathogenic bacteria, and lactic acid bacteria can survive in the agent for a longer time. However, no in vitro or in vivo experiments have shown that the agent can stimulate the growth and acid production of lactic acid bacteria. The application also does not suggest a therapeutic effect when lactose or glycogen alone, and any other sugars are used as active ingredients. GB2112285A discloses a vaginal cleansing lotion composition, which is a buffer solution composed of acetic acid or lactic acid plus sodium acetate, whose pH value is 5.71-6.2 as shown in the examples; it also contains a Lactobacillus nutrient, wherein the nutrient 1-2% (W / V) of glucose, unsaturated fatty acids are used, and monosaccharides and / or disaccharides are also mentioned broadly. The main pharmacological action mechanism of the agent is that a buffer solution composed of acetic acid or lactic acid plus sodium acetate can selectively inhibit bacteria without inhibiting Lactobacillus lactis, as described in the second and third claims disclosed in the application, And in vitro experiments as disclosed in the application show that the vaginal cleansing lotion has a strong inhibitory effect on a variety of pathogens, and lactic acid bacteria survive longer in the agent. However, there is no in vitro or in vivo experimental data showing that this lotion has the effect of stimulating the growth and acid production of Pestolactis lactis, and it does not suggest the pharmacological effect of glucose and any other sugars as the main active ingredient. In addition, the application incorrectly believed that lactobacillus adjusted the vaginal pH to about 5.8, as described in lines 20-23 on the first page of the specification of the application.
上述专利申请 EP-A-0257007与 GB2112285A公开的以乳酸、 乙酸以及其它选择性抑菌剂为主要活性成分的药剂,对病菌抑制作用 强而对乳酸杆菌无明显抑菌作用,可能间接有利于阴道中乳酸杵菌的 生长。 但这些药剂本身不能直接、 显著地促进乳酸杵菌生长, 其改变 阴道酸度的时效也较短暂,因而病人阴道中的生理性革兰氏阳性杵菌 群仍然很难恢复成为优势菌群, 阴道的酸度也很难真正恢复正常。 本发明的目的是提供刺激患者阴道中革兰氏阳性杆菌生长和产 酸、增强阴道酸度的药剂, 以及使用该药剂治疗阴道革兰氏阳性杆菌 减少、 阴道酸度减弱、 及相关阴道疾病的方法。  The above-mentioned patent applications EP-A-0257007 and GB2112285A disclose medicaments containing lactic acid, acetic acid, and other selective bacteriostatic agents as the main active ingredients, which have a strong inhibitory effect on germs and have no obvious bacteriostatic effect on lactic acid bacteria, which may indirectly benefit the vagina. Growth of P. lactis. However, these agents themselves can not directly and significantly promote the growth of Pedicillium lactis, and their time to change the vaginal acidity is relatively short. Therefore, it is still difficult for the physiological Gram-positive Pedicillary bacteria in the patient's vagina to recover to become the dominant flora. It's also difficult to really get back to normal. The object of the present invention is to provide a medicament for stimulating the growth and acid production of Gram-positive bacilli in a patient's vagina and enhancing vaginal acidity, and a method for using the medicament to treat a decrease in vaginal gram-positive bacillus, a decrease in vaginal acidity, and related vaginal diseases.
为了寻求一种刺激阴道中革兰氏阳性杆菌生长和产酸、增强阴道 酸度的药物, 本发明人进行了广泛的研究。对现有技术方案的各种药 剂进行实验, 均未发现有刺激革兰氏阳性杆菌生长的作用。本发明人 经反复实验、深入研究后非常意外地发现,蔗糖和麦芽糖各自在特定 的浓度和 pH值范围内均具有强的剌激革兰氏阳性杆菌生长和产酸 的作用。体外混合培养实验显示, 受试的这两种糖均能刺激革兰氏阳 性杆菌生长、 使其数量显著增加。 更令人意外的是, 尽管阴道 pH值 高于 4.6时即为病态、且绝大多数现有技术均很强调用于阴道的药剂 pH值须 4.0或更低,但本发明人发现蔗糖和麦芽糖在 pH值 4.1-7.2、 尤其在 5.0以上的条件下,具有刺激患者阴道革兰氏阳性杆菌生长和 产酸的作用, 能使患者阴道的 pH值降至 4.6以下; 而当 pH值为 4.0 或更低时却无显著刺激患者阴道革兰氏阳性杆菌生长和产酸的作 用, 患者阴道的 pH值反而难于降至 4.6以下。 基于上述发现, 通过 进一步研究本发明人完成了本发明。 发明概述 本发明提供一种刺激阴道革兰氏阳性杆菌生长、增强阴道酸度的 水基药剂, 其特征在于, 按药剂总体积计, 其含有总量为 2.5- 17%(W V)的蔗糖或 /和麦芽糖; 还可选择性地含有一种或多种选自 下组的糖: 葡萄糖、 果糖、 半乳糖、 甘露糖、 乳糖、 乳果糖、 海藻糖、 纤维二糖、 蜜二糖、 棉子糖、 麦芽寡糖、 异麦芽寡糖、 低聚果糖、 糊 精、 淀粉和糖原; 药剂 pH值范围为 4.1-7.2 , 可用药物可以接受的 酸或碱来调节; 可选择性地含有可药用的粘性基质;还可选择性地含 有有效量的抗真菌药物和 /或抗细菌药物。 In order to find a drug that stimulates the growth and acid production of Gram-positive bacilli in the vagina and enhances the vaginal acidity, the present inventors have conducted extensive research. Experiments on various agents in the prior art schemes have not been found to have the effect of stimulating the growth of Gram-positive bacilli. After repeated experiments and in-depth studies, the inventors have discovered very unexpectedly that each of sucrose and maltose has a strong effect on stimulating the growth and acid production of Gram-positive bacteria in a specific concentration and pH range. In vitro mixed culture experiments show that both sugars tested can stimulate Gram Yang The number of sexual bacilli grows significantly. More surprisingly, although the vaginal pH is ill when it is higher than 4.6, and most prior arts have emphasized that the pH value of vaginal agents must be 4.0 or lower, the inventors found that sucrose and maltose At pH 4.1-7.2, especially above 5.0, it can stimulate the growth and acid production of gram-positive bacilli in patients' vagina, which can reduce the patient's vaginal pH to below 4.6; and when the pH is 4.0 or When it is lower, it does not significantly stimulate the growth and acid production of Gram-positive bacteria in the vagina of the patient, and the pH of the patient's vagina is difficult to fall below 4.6. Based on the above findings, the present inventors have completed the present invention through further studies. SUMMARY OF THE INVENTION The present invention provides a water-based agent that stimulates the growth of vaginal Gram-positive bacteria and enhances vaginal acidity, and is characterized in that it contains 2.5-17% (WV) sucrose or / And maltose; may also optionally contain one or more sugars selected from the group consisting of glucose, fructose, galactose, mannose, lactose, lactulose, trehalose, cellobiose, melibiose, raffinose , Malto-oligosaccharides, isomalt-oligosaccharides, fructooligosaccharides, dextrin, starch and glycogen; the pH range of the agent is 4.1-7.2, which can be adjusted with pharmaceutically acceptable acids or bases; optionally contains pharmaceutically acceptable A sticky matrix; optionally can also contain an effective amount of an antifungal and / or antibacterial drug.
本发明还提供了蔗糖或 /和麦芽糖作为活性成分在制备刺激阴道 革兰氏阳性杆菌生长、 增强阴道酸度的药剂中的用途。  The present invention also provides the use of sucrose or / and maltose as an active ingredient in the preparation of a medicament that stimulates the growth of Gram-positive bacilli in the vagina and enhances the vaginal acidity.
本发明还涉及一种剌激阴道革兰氏阳性杵菌生长、增强阴道酸度 的方法, 其中给予有此需要的主体以治疗有效量的本发明的药剂。  The present invention also relates to a method for stimulating the growth of vaginal Gram-positive pestles and enhancing vaginal acidity, wherein a subject in need thereof is given a therapeutically effective amount of the agent of the present invention.
上述本发明的药剂、用途和治疗方法适用于治疗阴道革兰氏阳性 杆菌减少和阴道酸度减弱, 治疗伴有革兰氏阳性杆菌減少的阴道炎、 阴道菌群失调, 尤其是治疗细菌性阴道病。 发明详述 如上文提到的那样, 本发明涉及一种含有 2.5-17%(W/V)的一种 或多种如上定义的糖的 pH值为 4.1-7.2的刺激阴道革兰氏阳性杆菌 生长、 增强阴道酸度的水基药剂。 The above-mentioned medicament, use and treatment method of the present invention are suitable for treating a decrease in vaginal Gram-positive bacilli and a decrease in vaginal acidity, a treatment of vaginitis and a vaginal flora disorder accompanied by a decrease in Gram-positive bacilli, and particularly the treatment of bacterial vaginosis . Detailed description of the invention As mentioned above, the present invention relates to stimulating the growth and enhancement of Gram-positive bacilli in the vagina, which contains 2.5-17% (W / V) of one or more sugars as defined above with a pH of 4.1-7.2. Water-based agent for vaginal acidity.
在本发明的上述药剂中, 上述种类的糖可只选用一种, 也可两 种、 多种混合使用。 本发明所用己糖为 D-构型的, 淀粉可以是直链 或支链淀粉。 优选那些价廉、 来源丰富的糖。  Among the above-mentioned agents of the present invention, only one kind of the above-mentioned sugars may be selected, or two or more kinds may be mixed for use. The hexose used in the present invention is in the D-configuration, and the starch may be amylose or amylopectin. Preferable are those inexpensive and abundant sugars.
根据本发明, 药剂中糖组分的总含量为 2.5-17% ( W/V ) , 特 别是 2.5 - 16 % ( W/V ) , 优选含量为 8-14% ( W/V ), 特别优 选的含量为 10-13% ( W/V ), 特别是 10 - 12 % ( W/V )。 但与 蔗糖和 /或麦芽糖混合使用的其它种类的双糖用量不超过 [17 -蔗糖 和 /或麦芽糖含量】%;与蔗糖和 /或麦芽糖混合使用的己糖最大用量应 低于 0.42 X ( 17-所用双糖量) % ( W/V ) 。  According to the present invention, the total content of the sugar component in the medicament is 2.5-17% (W / V), especially 2.5-16% (W / V), preferably the content is 8-14% (W / V), and particularly preferred The content is 10-13% (W / V), especially 10-12% (W / V). However, the amount of other types of disaccharides mixed with sucrose and / or maltose should not exceed [17-sucrose and / or maltose content]%; the maximum amount of hexose used in combination with sucrose and / or maltose should be less than 0.42 X (17 -Amount of disaccharide used)% (W / V).
本申请上文和下文提及的重量 /体积含量( W/V )指每 100亳升 药剂中的克数。  The weight / volume content (W / V) mentioned above and below in this application refers to the number of grams per 100 liters of the drug.
按照优选或特别优选的糖浓度配制的药剂, 适合于各种病情、 尤 其是病情严重的病人, 其阴道分泌物 pH>5.0 , 涂片染色镜检革兰氏 阳性杆菌无或极少; 糖含量低于 8% ( W V ) 的药剂则仅适合于病 情较轻的病人, 其阴道分泌物 ρΗ>4.6 , 涂片染色检查有阳性杵菌, 但较阴性杵菌、 阴性球菌、 或阳性球菌少。  The medicament formulated according to the preferred or particularly preferred sugar concentration is suitable for various diseases, especially patients with severe conditions, whose vaginal secretion pH is greater than 5.0, and the smear staining microscopic examination of Gram-positive bacilli has little or no sugar; Drugs below 8% (WV) are only suitable for patients with mild disease, whose vaginal secretion is ρΗ> 4.6, and smear staining has positive pestis, but less than negative pestis, negative cocci, or positive cocci.
本发明药剂的 pH范围为 4.1— 7.2 , 优选 pH值范围为 4.5-6.5 。 药剂的 pH值可用任何药物可接受的酸或碱来调节。 优选乙酸、 乳酸 和氢氧化钠。调节本发明药剂 pH值的酸或碱的种类和浓度的选择在 本领域普通技术人员的知识范围之内。  The pH range of the agent of the present invention is 4.1-7.2, and the preferred pH range is 4.5-6.5. The pH of the agent can be adjusted with any pharmaceutically acceptable acid or base. Acetic acid, lactic acid and sodium hydroxide are preferred. The choice of the type and concentration of the acid or base that adjusts the pH of the agent of the invention is within the knowledge of one of ordinary skill in the art.
根据本发明, 本药剂中可包含粘性基质成分。 可选用黄原胶 (Xanthan Gum), 浓度为 1.0-2.2% ( W V ) , 优选浓度 1.4-2.0% ( W/V )。 黄原胶粘性高, 且对温度、 pH值变化稳定, 能使糖与 阴道粘膜比较均勾地接触、并停留较长时间,从而发挥刺激阴道革兰 氏阳性杆菌生长和产酸的作用。 本药剂亦可用本领域技术人员已知的其它适当的粘性载体基 质、 辅料成分等制成胶状剂、 软膏剂等。 According to the present invention, a viscous matrix component may be contained in the agent. Xanthan Gum can be used at a concentration of 1.0-2.2% (WV), preferably 1.4-2.0% (W / V). Xanthan has high viscosity, and is stable to changes in temperature and pH. It can make sugar and vaginal mucosa evenly contact and stay for a long time, so as to stimulate the growth and acid production of vaginal gram-positive bacilli. The agent can also be made into gels, ointments, etc. with other suitable viscous carrier bases, excipient ingredients and the like known to those skilled in the art.
根据本发明, 本药剂亦可不含粘性基质成分,但需用能浸吸药液 的阴道塞(棉球、 纱布球、 纱条等)给药, 同样能起刺激革兰氏阳性 杵菌生长和增强阴道酸度的作用。但若将不含粘性基质成分的本发明 药剂作为阴道清洁洗液使用时, 则不能很好地发挥其疗效, 因本发明 药剂需在阴道内停留一定时间才能刺激阴道中的革兰氏阳性杆菌生 长和产酸、 并实现本发明目的。  According to the present invention, the agent may not contain a viscous matrix component, but it needs to be administered with a vaginal plug (cotton ball, gauze ball, gauze strip, etc.) capable of inhaling the drug solution, which can also stimulate the growth of Gram-positive pestles and Enhances vaginal acidity. However, if the medicament of the present invention containing no viscous matrix component is used as a vaginal cleansing lotion, its efficacy cannot be exerted well, because the medicament of the present invention needs to stay in the vagina for a certain period of time to stimulate the Gram-positive bacilli in the vagina Grow and produce acid, and achieve the object of the present invention.
本发明药剂中糖组分是基本活性成分,单独与适当的药用载体組 合就能够实现本发明目的,但若在其中添加微量或少量氨基酸、 维生 素等类物质或富含氨基酸、 维生素的酵母浸出物等, 则效果更佳。 阴 道分泌物中天然含有微量氨基酸、 维生素等类物质。体外实验过程中 缺少微量氨基酸、 维生素等类物质的天然来源, 故用于体外实验的本 发明药剂应添加有少量这类物质。  The sugar component in the medicament of the present invention is a basic active ingredient, which can achieve the purpose of the present invention alone in combination with an appropriate pharmaceutical carrier, but if a trace amount or a small amount of amino acids, vitamins or the like is added thereto or the amino acid and vitamin-rich yeast is leached Objects, etc., the effect is better. The vaginal secretions naturally contain trace amounts of amino acids, vitamins and other substances. In the process of in vitro experiments, natural sources of trace amino acids, vitamins and other substances are lacking. Therefore, the agent of the present invention for in vitro experiments should be added with a small amount of such substances.
本发明药剂中还可含有有效量的抗真菌药物, 用于控制可能出现 的真菌生长增多。 抗真菌药物的例子有酮康唑、 曲康唑、 伊曲康唑、 氟康唑等。  The medicament of the present invention may also contain an effective amount of an antifungal drug for controlling the growth of fungi that may occur. Examples of antifungal drugs are ketoconazole, itraconazole, itraconazole, fluconazole and the like.
本发明药剂中也可以含有有效量的对革兰氏阴性细菌有抑菌、杀 菌作用、但对阳性杆菌无作用或作用弱的抗菌药物, 这样可以增强本 发明药剂对阴道感染或炎症的疗效。这种抗细菌药物的例子有多粘菌 素、 灭滴灵、 氨曲南等。  The agent of the present invention may also contain an effective amount of an antibacterial drug that has bacteriostatic and bactericidal effects on Gram-negative bacteria, but has no effect or weak effect on positive bacilli, so that the effect of the agent of the present invention on vaginal infection or inflammation can be enhanced. Examples of such antibacterial drugs are polymyxin, metronidazole, aztreonam and the like.
本发明药剂可按本领域技术人员已知的方法制备。  The medicament of the present invention can be prepared according to methods known to those skilled in the art.
当选用的糖組分不含淀粉或少含淀粉时,将糖组分与粘性辅料成 分混勾, 加蒸馏水, 搅拌使糖组分溶解、 粘性辅料成分溶胀呈均匀粘 性胶状; 若选用淀粉, 则直接加热, 使之成浆糊状, 粘性辅料成分可 加或不加; 用乳酸或氢氧化钠液调 pH值至预定值, 再经灭菌即可。 也可先灭菌, 再调 pH值。 灭菌可采用间歇灭菌, 具体方法是: 80 摄氏度 30分钟, 然后置 36摄氏度 8-12小时; 再 80摄氏度 30分钟, 然后置 36度 8-12小时; 再 80摄氏度 30分钟。 也可采用 116摄氏度 15-20分钟高压灭菌; 或将糖组分单独配制成溶液后滤过除菌, 再添 加到经高压灭菌的粘性胶状基质中。 When the sugar component selected does not contain starch or contains little starch, mix the sugar component with the viscous excipient component, add distilled water, and stir to dissolve the sugar component. The viscous excipient component swells into a uniform viscous gum; if starch is used, Then, it is directly heated to make it paste-like, and viscous auxiliary ingredients may be added or not added; the pH value is adjusted to a predetermined value with lactic acid or sodium hydroxide solution, and then sterilized. It can also be sterilized before adjusting the pH. Intermittent sterilization can be adopted. The specific method is: 80 degrees Celsius for 30 minutes, and then set at 36 degrees Celsius for 8-12 hours; then 80 degrees Celsius for 30 minutes, Then set it at 36 degrees for 8-12 hours; then at 80 degrees for 30 minutes. It can also be autoclaved at 116 ° C for 15-20 minutes; or the sugar component is separately prepared into a solution, filtered and sterilized, and then added to the autoclaved viscous gelatinous matrix.
本发明也可以通过将糖组分溶于水制成真溶液形式,用该溶液浸 泡阴道塞后给病人使用即可。  The present invention can also be made into a true solution by dissolving the sugar component in water, and the solution can be used for patients after soaking the vaginal plug.
本发明的药剂以糖类为活性组分, 具有良好的储存稳定性。 但 优选冷藏保存药剂, 或置阴凉处保存, 药剂酸碱度为中性也有利于糖 組分保持稳定。 本发明还涉及一种或多种如上定义的糖作为活性成分在制备刺 激阴道革兰氏阳性杵菌生长、增强阴道酸度的药物中的用途。本发明 所用己糖为 D-构型的, 淀粉可以是直链或支链淀粉。  The medicament of the present invention uses saccharides as an active component and has good storage stability. However, it is preferable to store the medicament in a refrigerated or cool place. The neutral pH of the medicament is also beneficial to the stability of the sugar component. The invention also relates to the use of one or more sugars as defined above as an active ingredient in the manufacture of a medicament that stimulates the growth of vaginal Gram-positive pestles and enhances vaginal acidity. The hexose used in the present invention is in the D-configuration, and the starch may be amylose or amylopectin.
本发明药物制备用途中的药物可用于刺激阴道革兰氏阳性杵菌生 长、 增强阴道酸度, 用于治疗阴道革兰氏阳性杆菌减少、 阴道酸度减 弱 ( pH值在 4.6以上)、 以及伴有阴道阳性杆菌减少的阴道炎、 阴 道菌群失调、 特别是细菌性阴道病。  The medicament in the preparation application of the present invention can be used to stimulate the growth of vaginal Gram-positive pestles, enhance vaginal acidity, be used to treat vaginal gram-positive bacilli, reduce vaginal acidity (pH above 4.6), and accompany vagina Positive bacilli reduce vaginitis, vaginal flora disorders, and especially bacterial vaginosis.
经体内、 体外实 明, 本发明的药剂具有很强的刺激阴道阳性 杵菌生长和产酸的作用, 可用于治疗阴道革兰氏阳性杵菌减少、 阴道 酸度减弱以及伴有革兰氏阳性杆菌减少的阴道炎、 阴道菌群失调、特 别是细菌性阴道病。  It has been proved in vivo and in vitro that the medicament of the present invention has a strong effect on stimulating the growth and acid production of vaginal positive pestles, and can be used to treat the decrease of vaginal gram-positive pestles, the weakening of vaginal acidity, and the accompanying gram-positive bacteria. Reduced vaginitis, vaginal flora disorders, and especially bacterial vaginosis.
因此, 本发明还涉及一种刺激阴道革兰氏阳性杵菌生长、增强阴 道酸度、 治疗阴道革兰氏阳性杆菌减少、 阴道酸度减弱、 以及伴有革 兰氏阳性杆菌减少的阴道炎、 阴道菌群失调、特别是细菌性阴道病的 方法, 其中包括给予有此需要的患者以治疗有效量的上述本发明药 剂。  Therefore, the present invention also relates to stimulating the growth of vaginal Gram-positive pestles, enhancing vaginal acidity, treating a decrease in vaginal Gram-positive bacilli, weakening vaginal acidity, and vaginitis accompanied by a decrease in Gram-positive bacilli, vaginal bacteria A method for hereditary disorders, particularly bacterial vaginosis, which comprises administering to a patient in need thereof a therapeutically effective amount of the above-mentioned agent of the present invention.
本发明药剂和本发明治疗方法中的给药方法是阴道内局部给 药。对于含有粘性基质或其它载体基质的本发明药剂, 可以直接施用 于患者阴道内。 对于真溶液剂型的本发明药剂, 可用于浸泡阴道塞, 然后放置本发明药剂浸泡的阴道塞于患者阴道内。 The medicament of the present invention and the method of administration in the treatment method of the present invention are local administration in the vagina. For the agent of the present invention containing a viscous matrix or other carrier matrix, it can be administered directly into a patient's vagina. The medicament of the present invention in a true solution form can be used to soak a vaginal plug, The vagina soaked with the agent of the present invention is then placed in the patient's vagina.
本发明药剂和本发明治疗方法中的用药剂量, 为含 8-14% ( W/V ) 活性成分糖的本发明药剂每次阴道内给药 3-5亳升、 每日 1-3次, 使每日用药的总糖量为 0.24-2.1克。 一般睡前和晨起时给药 即可, 少数病人中午需加用一次药。 阴道菌群严重异常的病人, 其阴 道分泌物 pH>5.0, 涂片染色检查革兰氏阳性杆菌无或极少, 治疗用 药量需较大, 每日用药总糖量一般在 0.8克以上; 病情较轻的病人, 其阴道分泌物 5.0>pH>4.6 , 涂片染色检查有阳性杵菌, 但较阴性杵 菌、 阴性球菌、 或阳性球菌少, 治疗用药量较小, 每曰用药总糖量一 般在 0.8克以下。  The dosage of the medicament of the present invention and the treatment method of the present invention is the medicament of the present invention containing 8-14% (W / V) active ingredient sugar, which is administered 3-5 liters per vaginal administration, 1-3 times a day, The total amount of sugar used daily is 0.24-2.1 grams. It is usually given before bedtime and in the morning. A few patients need to take the medicine once at noon. Patients with severely abnormal vaginal flora, whose vaginal secretion pH is greater than 5.0, have no or very few Gram-positive bacilli by smear staining, the amount of medication required is large, and the total daily amount of sugar is generally above 0.8 g; Lighter patients, whose vaginal secretion is 5.0> pH> 4.6, smear staining test has positive pestles, but less than negative pestles, negative cocci, or positive cocci, the amount of medication is small, and the total amount of sugar per medication Generally below 0.8 grams.
使用本发明药剂治疗过程中应每日观察病人临床症状并检测阴 道 pH值的变化,条件许可时还应做阴道分泌物涂片染色镜检了解菌 群的变化, 并根据病情变化调整用药剂量和疗程。 一般来讲, 使用本 发明药剂 1-3天即可产生显著疗效, 病人症状显著好转或消失、 阴道 pH值降至正常范围以及阴道阳性杵菌恢复为优势菌群。 此时应停药 或减量、 或小剂量维持治疗。  During the treatment with the agent of the present invention, the clinical symptoms of the patient should be observed daily and changes in the vaginal pH value should be checked. Vaginal secretion smear staining microscopy should be performed to understand the changes in the flora when conditions permit, and the dosage and Course of treatment. Generally speaking, using the agent of the present invention can produce a significant effect within 1-3 days, the patient's symptoms significantly improve or disappear, the vaginal pH value drops to the normal range, and the vaginal positive pestles return to the dominant flora. At this time, the drug should be discontinued or reduced or maintained in low doses.
在本发明的方法中, 可给予患者仅含本发明的糖作为活性成分的 药剂, 也可给予含有糖、 抗真菌药物和 /或抗细菌药物的本发明药剂; 或者,可将仅含本发明的糖作为活性成分的药剂与适当的抗真菌药物 或抗细菌药物结合使用。在后一种情况下,本发明药剂可与抗真菌剂 和抗细菌剂同时给药, 或在抗真菌剂之前给药, 或在抗细菌剂之后给 药。  In the method of the present invention, a medicament containing only the sugar of the present invention as an active ingredient may be administered to a patient, and a medicament of the present invention containing sugar, an antifungal drug and / or an antibacterial drug may be administered; or, the medicament containing only the present invention may be administered. The sugar is used as an active ingredient in combination with an appropriate antifungal or antibacterial drug. In the latter case, the agent of the present invention may be administered simultaneously with the antifungal agent and the antibacterial agent, or administered before the antifungal agent, or administered after the antibacterial agent.
本发明药剂使用后可使患者的临床症状迅速緩解,阴道内革兰氏 阳性杵菌增加、 阴道酸度增强 pH值降至 4.0-4.6 , 而阴道内异常生 长的阴性杵菌、 阴性球菌等有害菌显著减少、 甚至消失。 因此, 本发 明药剂是一种成分简单、 易于制备、 使用方便而且疗效可靠的药剂。  After the use of the agent of the present invention, the clinical symptoms of patients can be quickly relieved, Gram-positive pestles increased in the vagina, pH value of the vaginal acidity increased to 4.0-4.6, and harmful bacteria such as negative pestles and negative cocci that grow abnormally in the vagina. Significantly reduced or even disappeared. Therefore, the medicine of the present invention is a medicine with simple ingredients, easy preparation, convenient use and reliable curative effect.
以下参照下列实验实施例说明本发明药剂或方法的有效性。 实验实例 1 本发明药剂的体外实验 1 :本发明药剂对革兰氏阳性杆菌生长和产酸 的刺激作用 实验方法: The effectiveness of the medicament or method of the present invention is illustrated below with reference to the following experimental examples. Experimental example 1 In vitro experiment 1 of the agent of the present invention: Experimental method for stimulating the growth and acid production of Gram-positive bacteria by the agent of the present invention:
( 1 ) 准备制剂: 选用蔗糖, 按照前述制备方法, 准备下述制 剂,  (1) Preparation of preparation: selecting sucrose and preparing the following preparation according to the aforementioned preparation method,
蔗糖 10.% 酵母浸出粉 1.0 %、 黄原胶 1.6 %, 调 pH5.0 ;  Sucrose 10.% yeast extract 1.0%, xanthan gum 1.6%, adjust pH 5.0;
上述药剂经灭菌处理后分装试管, 每管 5毫升, 预还原备用。  After the above medicament is sterilized, the test tubes are divided into 5 ml tubes and pre-reduced for future use.
( 2 ) 准备标本液: 取典型细菌性阴道病患者的阴道分泌物拭 子, 立即于 2ml灭菌大豆胰晦蛋白胨培养液(经预还原处理) 中洗 脱成混悬液, 即为标本液。 该分泌物经涂片染色镜检, 为复杂菌群, 以多种革兰氏阴性杆菌、 阴性球菌、 及阳性球菌为主, 革兰氏阳性杆 菌几乎未见。  (2) Prepare the sample solution: Take a vaginal secretion swab of a typical bacterial vaginosis patient, and immediately elute it into a suspension in 2 ml of sterilized soybean tryptone peptone culture solution (pre-reduced), which is the sample solution. . The secretion was examined by smear staining and microscopy, and it was a complex flora. It was mainly composed of a variety of Gram-negative bacilli, negative cocci, and positive cocci. Gram-positive Bacillus was hardly found.
( 3 ) 立即接种上述刚备好的标本液于药剂管中, 每管接种 10 微升, 混匀, 置 37摄氏度、 厌氧培养, 分别于 10小时、 24小时取 培养物涂片染色观察, 测培养物 pH 。 结果:  (3) Immediately inoculate the above-prepared specimen solution in the drug tube, inoculate 10 μl of each tube, mix well, set at 37 ° C, and anaerobic culture, and take the culture smear for staining observation at 10 and 24 hours, respectively. Measure the culture pH. Results:
如表 1所示,尽管标本镜检几乎未见革兰氏阳性杵菌,但接种到 本发明制剂中后培养, 革兰氏阳性杆菌显著生长并伴有药剂 pH 下 降。 表 1. 本发明药剂对革兰氏阳性杵菌生长和产酸的选择性促进作用 制剂
Figure imgf000013_0001
制剂 ιο小时 培养 24小时
As shown in Table 1, although almost no Gram-positive pestles were detected by microscopic examination of the specimen, after inoculation into the preparation of the present invention, the Gram-positive bacteria grew significantly with a decrease in the pH of the agent. Table 1. Preparations of the present invention for the selective promotion of Gram-positive pestles growth and acid production
Figure imgf000013_0001
Preparations οοοh culture for 24 hours
中糖 中细菌 pH  Medium sugar Medium bacteria pH
种类 种类 细 菌 细 菌 蔗 糖 G+b,- 5.0 G+b,+++ 5.0 G+b,+++ 4.0  Species Species Fine bacteria Fine bacteria Sucrose G + b,-5.0 G + b, +++ 5.0 G + b, +++ 4.0
G-b,→ G-b,++ G-b,++  G-b, → G-b, ++ G-b, ++
G-c,+++ G-c+ G-c,+  G-c, +++ G-c + G-c, +
G+c-H- G+C ++  G + c-H- G + C ++
#1: G+b : 革兰氏阳性杆菌; G-b : 革兰氏阴性杵菌; G+c : 革 兰氏阳性球菌; G-c : 革兰氏阴性球菌。 # 1: G + b: Gram-positive bacilli; G-b: Gram-negative pestles; G + c: Gram-positive cocci; G-c: Gram-negative cocci.
#2: +: 每油镜视野 1-9个菌; ++: 每油镜视野约 10-99个菌; +++: 细菌多, 100个至难于计数; ++++: 细菌密集、 成团。  # 2: +: 1-9 bacteria per field of view of oil lens; ++: about 10-99 bacteria per field of view of oil lens; +++: 100 bacteria are difficult to count; ++++: bacteria are dense, Into a group.
结论:  in conclusion:
本发明制剂有刺激革兰氏阳性杆菌生长、 产酸的作用。 实验实例 2 本发明药剂的体外实验 2:蔗糖和麦芽糖与其它糖类对革兰氏阳性杵 菌生长和产酸的刺激作用的比较  The preparation of the invention has the effects of stimulating the growth and acid production of Gram-positive bacteria. Experimental Example 2 In vitro experiment of the agent of the present invention 2: Comparison of sucrose and maltose and other sugars on the stimulating effects of Gram-positive pestles growth and acid production
实验方法:  experimental method:
( 1 )配制药剂: 分别选用葡萄糖、 果糖、 半乳糖、 甘露糖、 麦 芽糖、 蔗糖、 乳糖、 乳果糖、 纤维二糖、 海藻糖、 蜜二糖、 棉子糖、 麦芽寡糖、 异麦芽寡糖、 低聚果糖、 糊精、 淀粉、 糖原按照前述制备 方法, 配制下述药剂:  (1) Formulation: glucose, fructose, galactose, mannose, maltose, sucrose, lactose, lactulose, cellobiose, trehalose, melibiose, raffinose, malto-oligosaccharide, and isomalt-oligosaccharide , Fructooligosaccharide, dextrin, starch, glycogen According to the aforementioned preparation method, the following agents are formulated:
A. 5%葡萄糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ;  A. 5% glucose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
B. 5%果糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; C. 5%半乳糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; B. 5% fructose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2; C. 5% galactose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
D. 5%甘露糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ;  D. 5% mannose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
E. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; E. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
F. 10.0%蔗糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; F. 10.0% sucrose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
G. 10.0%乳糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ;  G. 10.0% lactose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
H. 10.0%乳果糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; H. 10.0% lactulose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
I. 10.0%纤维二糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; J. 10.0%海藻糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; K. 10.0%蜜二糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; L. 10.0%棉子糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; M. 10.0%麦芽寡糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; N. 10.0%异麦芽寡糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2; I. 10.0% cellobiose, 1.0% yeast extract, 1.6% xanthan gum, adjusted pH 6.2; J. 10.0% trehalose, 1.0% yeast extract, 1.6% xanthan gum, adjusted pH 6.2; K. 10.0 % Melibiose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2; L. 10.0% raffinose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2; M. 10.0% malt Oligosaccharide, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2; N. 10.0% isomalt oligosaccharide, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
O. 10.0%低聚果糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; P. 10.0%糊精、 1.0%酵母浸出粉、 0.5%黄原胶, 调 pH 6.2 ;  O. 10.0% fructooligosaccharide, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2; P. 10.0% dextrin, 1.0% yeast extract, 0.5% xanthan gum, adjust pH 6.2;
Q. 10.0%淀粉、 1.0%酵母浸出粉, 调 pH 6.2 Q. 10.0% starch, 1.0% yeast extract, adjust pH 6.2
R. 10.0%糖原、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; R. 10.0% glycogen, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
( 2 ) 准备实验管: 上述药剂配制好后分装试管, 每管 5亳升, 灭菌, 备用。  (2) Prepare test tubes: After preparing the above reagents, aliquot test tubes, sterilize each tube, sterilize, and set aside.
( 3 ) 准备标本液: 取典型细菌性阴道病患者的阴道分泌物拭 子, 立即于 2毫升灭菌大豆胰酶蛋白胨培养液中洗脱成混悬液, 即为 标本液。 该分泌物经涂片染色镜检, 为复杂菌群, 以多种革兰氏阴性 杆菌、 阴性球菌、 及阳性球菌为主, 革兰氏阳性杆菌几乎未见。  (3) Prepare the sample solution: Take a vaginal secretion swab of a typical bacterial vaginosis patient, and immediately elute the suspension in 2 ml of sterilized soybean trypsin peptone culture solution, which is the sample solution. The secretion was examined by smear staining and microscopic examination, and it was a complex flora, mainly a variety of Gram-negative bacilli, negative cocci, and positive cocci, and almost no Gram-positive bacilli were found.
( 4 )接种、 培养与结果观察: 立即接种上述刚备好的标本液于 各实验管中, 每管接种 10微升, 混勾, 37摄氏度、 烛缸法培养, 分 别于 24小时、 48小时取培养物涂片染色观察, 测培养物 pH。  (4) Inoculation, cultivation and observation of the results: Immediately inoculate the freshly prepared specimen solution into each experimental tube, inoculate 10 μl of each tube, mixed hook, culture at 37 ° C, and candle-cylinder method for 24 hours and 48 hours, respectively. Take the culture smear for staining observation and measure the pH of the culture.
结果:  Results:
( 1 )如表 2所示,尽管阴道分泌物标本中的革兰氏阳性杵菌极 少,但接种到各糖药剂实验管中培养 24、 48小时,却均有大量革兰 氏阳性杆菌生长, 大多数实验管同时还伴有药剂 pH值不同程度地下 降, 显示含 糖、麦芽糖或按照本发明可与它们混合的其它糖的制剂 对革兰氏阳性杆菌生长都具有刺激作用。 (1) As shown in Table 2, despite the presence of Gram-positive pestles in vaginal secretion specimens Less, but when inoculated into each sugar reagent test tube and cultured for 24 or 48 hours, a large number of gram-positive bacilli are grown, and most of the test tubes are also accompanied by a decrease in the pH of the drug to varying degrees, showing sugar, maltose, or The preparation of other sugars which can be mixed with them according to the present invention have a stimulating effect on the growth of Gram-positive bacilli.
( 2 )如表 2所示,所有实验管经 24、 48小时培养, 以含 10% 麦芽糖和 10%蔗糖的本发明药剂实验管的 pH值最低, 提示麦芽糖、 蔗糖被革兰氏阳性杆菌代谢利用的速度快, 麦芽糖、蔗糖对革兰氏阳 性杆菌生长和产酸的刺激作用强于其余种类的寡糖和多糖。 表 2. 蔗糖和麦芽糖与其它糖类对革兰氏阳性杆菌生长和产酸的刺激 作用的比较 药剂 蛣养 24小时 培养 8小时  (2) As shown in Table 2, all experimental tubes were cultured for 24 or 48 hours, and the pH value of the experimental tubes containing 10% maltose and 10% sucrose was the lowest, indicating that maltose and sucrose were metabolized by Gram-positive bacteria The utilization rate is fast. The stimulating effects of maltose and sucrose on the growth and acid production of Gram-positive bacilli are stronger than those of other types of oligosaccharides and polysaccharides. Table 2. Comparison of the effects of sucrose and maltose and other sugars on the growth and acid production of Gram-positive bacteria.
中糖 中细菌 pH  Medium sugar Medium bacteria pH
种类 种类 细 菌 PH 细 菌 PH  Species species
葡萄糖 Ob,- 62 G+b,++ 6.4 G+b,+++ 62 Glucose Ob,-62 G + b, ++ 6.4 G + b, +++ 62
G-b,"H-H- G-b,+ G-b,+  G-b, "H-H- G-b, + G-b, +
G-C,-H- (- G-c- G-C, -H- (-G-c-
G^,++ G+t,- G+C-H-G ^, ++ G + t,-G + C-H-
G+b,- 62 5.4-5.8 G+b,+ + 5.4-5.8G + b,-62 5.4-5.8 G + b, + + 5.4-5.8
G-b,++++ G-b,+ G-b,+ G-b, ++++ G-b, + G-b, +
G-C,-I-H- G-c- G-c,-
Figure imgf000015_0001
GC, -IH- Gc- Gc,-
Figure imgf000015_0001
半錄 G+b,- 62 G+b,++ 6.7 G+b,+ 6.7 G + b,-62 G + b, ++ 6.7 G + b, + 6.7
G-b,++++ G-b,- G-b,+  G-b, ++++ G-b,-G-b, +
G-c,+++ G-c- G-c- G-c, +++ G-c- G-c-
G+c,++ G+C++ G + c, ++ G + C ++
■ G+b,- 62 G b,++ 6.4 G+b,+++ 5.8 -π- ■ G + b,-62 G b, ++ 6.4 G + b, +++ 5.8 -π-
+ '3+3 + '3 + 3
-' -' D  -'-' D
-HH-f-'q-O -HH-f-'q-O
8 Γ9 -'q+D8 Γ9 -'q + D
+•3+3 + '3+3+ • 3 + 3 + '3 + 3
4^ 4 ^
+++'q-D  +++ 'q-D
++'q+D 8¾ Γ9 -'q+D  ++ 'q + D 8¾ Γ9 -'q + D
+^  + ^
•H-f+'q-O • H-f + 'q-O
+++'q+3 Γ9 -'q+D  +++ 'q + 3 Γ9 -'q + D
-' D -'D
+'q-3  + 'q-3
8'S ++'q+D Γ9  8'S ++ 'q + D Γ9
+•30 + • 30
-' 9 -' 9
- 'q-o +'q-o -'q-o +' q-o
Figure imgf000016_0001
Figure imgf000016_0001
+•3+0 ^
Figure imgf000016_0002
-' o 4^
+ • 3 + 0 ^
Figure imgf000016_0002
-'o 4 ^
SC99Z/66 O -si- SC99Z / 66 O -si-
-' o -'o
-H-H-'q-3  -H-H-'q-3
Γ9 ++'q+o Z/9 Γ9 -'q+D 纏  Γ9 ++ 'q + o Z / 9 Γ9 -'q + D
+^  + ^
- ">D -' 9  -"> D-'9
+'q-3  + 'q-3
8'S ++'q+D Γ9 Γ9 -'q+3 挪  8'S ++ 'q + D Γ9 Γ9 -'q + 3
-' D  -'D
-H-H-'q- -H-H-'q-
8¾ +++'q+D Γ9 Γ9 8¾ +++ 'q + D Γ9 Γ9
-' D -' 3 -'D-' 3
++¾  ++ ¾
Γ9 +++'q+D 8'S +++'q+9 Γ9 -'q+D  Γ9 +++ 'q + D 8'S +++' q + 9 Γ9 -'q + D
+'q-o -Η- -'q-D + 'q-o -Η- -'q-D
8'S 8'S Γ9 -'q+o m  8'S 8'S Γ9 -'q + o m
++'q-o +'q-9  ++ 'q-o +' q-9
8'S L'9 ++'q+9 Γ9 -'q+3  8'S L'9 ++ 'q + 9 Γ9 -'q + 3
+^ ++^  + ^ ++ ^
-' D  -'D
8'S Γ9 Γ9 -'q+3 ^-章8'S Γ9 Γ9 -'q + 3 ^ -chapter
LLZOOmSiD/lDd S£99Z/66 OW G+b,- 62 G+b,++ 6.4 G+b,++ + LLZOOmSiD / lDd S £ 99Z / 66 OW G + b,-62 G + b, ++ 6.4 G + b, ++ +
G-b, +-H- G-b,++ G-b,++  G-b, + -H- G-b, ++ G-b, ++
G-C, - + G-C- G-C- G-C,-+ G-C- G-C-
G . + 结论: 本发明药剂中的糖组分可以是 糖、麦芽糖或其混合物或 与上述所定义的其它糖的混合物。 实验实例 3 本发明药剂的体外实验 3:本发明药剂对革兰氏阳性杆菌生长和产酸 的刺激作用 实验方法: G. + Conclusion: The sugar component in the agent of the present invention may be sugar, maltose or a mixture thereof or a mixture with other sugars as defined above. Experimental example 3 In vitro experiment of the agent of the present invention 3: Stimulation effect of the agent of the present invention on the growth and acid production of Gram-positive bacilli Experimental method:
( 1 )配制药剂: 分别选用蔗糖、 麦芽糖按照前述制备方法, 配制下 述药剂:  (1) Preparation of medicament: The following medicaments are prepared by using sucrose and maltose respectively according to the aforementioned preparation method:
A. 2.5%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; A. 2.5% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
B. 2.5%蔗糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; B. 2.5% sucrose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
( 2 ) 准备实验管: 上述药剂配制好后分装试管, 每管 5毫升, 灭菌, 备用。  (2) Prepare experimental tubes: After preparing the above reagents, aliquot test tubes, 5ml per tube, sterilize, and set aside.
( 3 ) 准备标本液: 取典型细菌性阴道病患者的阴道分泌物拭 子, 立即于 2毫升灭菌大豆胰晦蛋白胨培养液中洗脱成混悬液, 即为 标本液。 该分泌物经涂片染色镜检, 为复杂菌群, 以多种革兰氏阴性 杆菌、 阴性球菌、 及阳性球菌为主, 革兰氏阳性杆菌几乎未见。  (3) Prepare the sample solution: Take a vaginal secretion swab of a typical bacterial vaginosis patient and immediately elute it into a suspension in 2 ml of sterilized soy tryptone culture medium, which is the sample solution. The secretion was examined by smear staining and microscopic examination, and it was a complex flora, mainly a variety of Gram-negative bacilli, negative cocci, and positive cocci.
( 4 ) 接种、 培养与结果观察: 立即接种上述刚备好的标本液 于各实验管中, 每管接种 10微升, 混勾, 37摄氏度、 烛缸法培养, 分别于 24小时、 48小时取培养物涂片染色观察, 测培养物 pH 。  (4) Inoculation, cultivation and results observation: Immediately inoculate the freshly prepared specimen solution into each experimental tube, inoculate 10 μl each tube, mixed hook, 37 ° C, candle-cylinder culture, respectively, for 24 hours and 48 hours. Take the culture smear for staining and observation, and measure the pH of the culture.
结果: 如表 3所示,尽管阴道分泌物标本中的革兰氏阳性杆菌极少,但 接种到各种本发明药剂实验管中培养 24、 48小时,却均有革兰氏阳 性杆菌生长, 显示含糖量为 2.5%的各种药剂对革兰氏阳性杆菌生长 具有一定的刺激作用。 result: As shown in Table 3, although there are very few Gram-positive bacilli in vaginal secretion specimens, when inoculated into various experimental tubes of the present invention and cultured for 24 or 48 hours, all Gram-positive bacilli have grown, showing that Various agents with a sugar content of 2.5% can stimulate the growth of Gram-positive bacteria.
表 3. 本发明药剂对革兰氏阳性杆菌生长和产酸的选择性促进作用 药剂 接 ¾? 药剂 培养 24小时 培养 8小时 Table 3. Selective effects of the agents of the present invention on the growth and acid production of Gram-positive bacteria. Pharmacy 24 hours 8 hours
中糖 中细菌 pH  Medium sugar Medium bacteria pH
种类 种类 细 菌 pH 细 菌 PH  Species Species pH bacteria pH bacteria
G+b,- 62 G+b,+ 7.0 G+b, - + 6.4 G + b,-62 G + b, + 7.0 G + b,-+ 6.4
G-b,++++ G-b,+++ G-b,+ G-b, ++++ G-b, +++ G-b, +
G-C+++  G-C +++
G+c,++ G+c,- G + c, ++ G + c,-
G+b,- 62 G+b,+ 62 G+b,+ 6.7G + b,-62 G + b, + 62 G + b, + 6.7
G-b,++++ G-b,+ G~b,++G-b, ++++ G-b, + G ~ b, ++
Figure imgf000019_0001
Figure imgf000019_0001
G+c+ G+c +  G + c + G + c +
结论:  in conclusion:
含 2.5%蔗糖、 麦芽糖的本发明药剂具有一定的刺激革兰氏阳性 杆菌生长的作用。 实验实例 4  The agent of the present invention containing 2.5% sucrose and maltose has a certain effect of stimulating the growth of Gram-positive bacilli. Experimental example 4
本发明药剂的体外实验 4:本发明药剂对革兰氏阳性杆菌生长和产酸 的刺激作用 In vitro experiment of the agent of the present invention 4: Stimulation of the agent of the present invention on the growth and acid production of Gram-positive bacilli
实验方法:  experimental method:
( 1 )准备药剂: 分别选用蔗糖和麦芽糖, 按照前述制备方法, 配制 下述药剂:  (1) Preparation of medicaments: Sucrose and maltose are selected respectively, and the following medicaments are prepared according to the aforementioned preparation method:
A. 17.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; A. 17.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2;
B. 17.0%蔗糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH 6.2 ; ( 2 ) 准备实验管: 上述药剂配制好后分装试管, 每管 5亳升, 灭菌, 备用。 B. 17.0% sucrose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.2; (2) Preparation of test tubes: After the above reagents are prepared, aliquot test tubes, each tube is 5 liters, sterilize, and set aside.
( 3 ) 准备标本液: 取典型细菌性阴道病患者的阴道分泌物拭 子, 立即于 2毫升灭菌大豆胰酶蛋白胨培养液中洗脱成混悬液, 即为 标本液。 该分泌物经涂片染色镜检, 为复杂菌群, 以多种革兰氏阴性 杆菌、 阴性球菌、 及阳性球菌为主, 革兰氏阳性杆菌几乎未见。  (3) Prepare the sample solution: Take a vaginal secretion swab of a typical bacterial vaginosis patient, and immediately elute the suspension in 2 ml of sterilized soybean trypsin peptone culture solution, which is the sample solution. The secretion was examined by smear staining and microscopic examination, and it was a complex flora, mainly a variety of Gram-negative bacilli, negative cocci, and positive cocci, and almost no Gram-positive bacilli were found.
( 4 ) 接种、 培养与结果观察: 立即接种上述刚备好的标本液 于各实验管中, 每管接种 10微升, 混匀, 37摄氏度、 烛缸法培养, 分别于 24小时、 48小时取培养物涂片染色观察, 测培养物 pH 。  (4) Inoculation, culture and results observation: Immediately inoculate the freshly prepared specimen solution into each experimental tube, inoculate 10 μl of each tube, mix and incubate at 37 ° C and candle-cylinder method for 24 hours and 48 hours, respectively. Take the culture smear for staining and observation, and measure the pH of the culture.
结果:  Results:
如表 4所示,尽管阴道分泌物标本中的革兰氏阳性杆菌极少, 但 接种到各本发明药剂实验管中培养 24 、 48小时,却均有大量革兰氏 阳性杆菌生长, 同时还伴有药剂 pH值显箸的下降, 显示含糖量为 17%的各种本发明药剂对革兰氏阳性杵菌生长具有显著刺激作用。 表 4. 本发明药剂对革兰氏阳性杵菌生长和产酸的选择性促进作用 药剂 接 药剂 培养 24小时 培养 8小时  As shown in Table 4, although there are very few Gram-positive bacteria in vaginal secretion specimens, a large number of Gram-positive bacteria have been grown when inoculated into the experimental tubes of the agents of the present invention for 24 to 48 hours, and at the same time, Accompanied by a significant decrease in the pH of the agent, it is shown that the various agents of the present invention with a sugar content of 17% have a significant stimulating effect on the growth of Gram-positive pestles. Table 4. Selective effects of the agents of the present invention on the growth and acid production of Gram-positive pestles
中糖 中细菌 pH  Medium sugar Medium bacteria pH
种类 种类 细 菌 pH 细 菌 PH  Species Species pH bacteria pH bacteria
麦絲 G+b,- 62 G+b,+++ 5.4 5.1 Max G + b,-62 G + b, +++ 5.4 5.1
G-b,++++ G-b,+ G~b,++  G-b, ++++ G-b, + G ~ b, ++
G-c,+++ G-c- G-c, +++ G-c-
Gtc,+ G+C ++ Gtc, + G + C ++
m G+b,- 62 G+b,++ 62 G+b, 5.4  m G + b,-62 G + b, ++ 62 G + b, 5.4
G-b, -H-H- G-b,++ G-b,++  G-b, -H-H- G-b, ++ G-b, ++
G-c,+++ G<,- G-c- G-c, +++ G <,-G-c-
G+C, -f G C,+ 结论: G + C, -f GC, + in conclusion:
含 17%蔗糖或麦芽糖的本发明药剂具有刺激革兰氏阳性杵菌生 长的作用。 实验实例 5  The agent of the present invention containing 17% sucrose or maltose has the effect of stimulating the growth of Gram-positive pestles. Experimental example 5
本发明药剂的体外实验 5 :本发明药剂 pH值对革兰氏阳性杵菌生长 和产酸的影响 实验方法 In vitro experiment 5 of the agent of the present invention: Effect of the pH value of the agent of the present invention on the growth and acid production of Gram-positive pestles
( 1 ) 准备药剂: 用麦芽糖按照前述制备方法, 准备下述药剂: (1) Preparation of medicament: Use maltose to prepare the following medicament according to the aforementioned preparation method:
A. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 4.4 ;A. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 4.4;
B. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 4.8 ;B. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 4.8;
C. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 5.1 ;C. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 5.1;
D. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 5.4 ;D. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 5.4;
E. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 5.8 ;E. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 5.8;
F. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 6.4 ;F. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.4;
G. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 6.8 ;G. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 6.8;
H. 10.0%麦芽糖、 1.0%酵母浸出粉、 1.6%黄原胶, 调 pH值 7.2 ; H. 10.0% maltose, 1.0% yeast extract, 1.6% xanthan gum, adjust pH 7.2;
( 2 ) 准备实验管 ·· 上述药剂配制好后分装试管, 每管 5亳升, 灭菌, 备用。  (2) Prepare the test tube ·· After preparing the above reagents, aliquot the test tubes, each tube is 5 liters, sterilize, and set aside.
( 3 ) 准备标本液: 取典型细菌性阴道病患者的阴道分泌物拭 子, 立即于 2毫升灭菌大豆胰鲦蛋白胨培养液中洗脱成混悬液, 即为 标本液。 该分泌物经涂片染色镜检, 为复杂菌群, 以多种革兰氏阴性 杆菌、 阴性球菌、 及阳性球菌为主, 革兰氏阳性杆菌几乎未见。  (3) Prepare the sample solution: Take a vaginal secretion swab of a typical bacterial vaginosis patient, and immediately elute it into a suspension in 2 ml of sterilized soybean tryptone peptone culture solution, which is the sample solution. The secretion was examined by smear staining and microscopic examination, and it was a complex flora, mainly a variety of Gram-negative bacilli, negative cocci, and positive cocci, and almost no Gram-positive bacilli were found.
( 4 ) 立即接种上述刚备好的标本液于实验管中, 每管接种 10 微升, 混匀, 置 37摄氏度、 烛缸法培养, 分别于 24小时、 48小时 取培养物涂片染色观察, 测培养物 pH。  (4) Immediately inoculate the freshly prepared specimen solution into experimental tubes, inoculate 10 μl of each tube, mix well, incubate at 37 degrees Celsius, and use the candle-cylinder method. Take the culture smears for staining at 24 and 48 hours, respectively. , Measure the pH of the culture.
结果: 如表 5所示, result: As shown in Table 5,
( 1 )在本发明药剂 pH值为 4.4时, 培养 48小时后药剂中生 长的革兰氏阳性杆菌很少。  (1) When the agent of the present invention has a pH of 4.4, there are few Gram-positive bacilli that grow in the agent after 48 hours of culture.
( 2 )本发明药剂 pH值 5.4-7.2时革兰氏阳性杆菌生长好, 24 小时革兰氏阳性杆菌生长、 pH值下降, 48小时革兰氏阳性杆菌量 多、 pH值降至 4.1 - 4.4左右。 表 5. 不同 pH值对本发明药剂药效的影响 培养 24小时 培养 48小时  (2) Gram-positive bacilli grow well when the pH of the agent of the present invention is 5.4-7.2, the Gram-positive bacillus grows and the pH value decreases in 24 hours, the amount of Gram-positive bacilli is large in 48 hours, and the pH value drops to 4.1-4.4 about. Table 5.Effects of different pH values on the efficacy of the agents of the present invention
中糖 的细菌  Bacteria in sugar
种类 种类 细 菌 pH 细 菌 pH  Species Species pH
麦絲 G+b,- 4.4 4.4 G+b , 偶见 4.4 Max G + b,-4.4 4.4 G + b, occasionally 4.4
G-b,++++ G-b,++ G-b,++  G-b, ++++ G-b, ++ G-b, ++
G-c,+++ G-C- G-c, +++ G-C-
G+c,++ G t,-G + c, ++ G t,-
G b,- 4.8 G+b,+ 4.8 G+b,+ 4.44.8G b,-4.8 G + b, + 4.8 G + b, + 4.44.8
G-b,++++ G-b,++ G-b,++ G-b, ++++ G-b, ++ G-b, ++
G-C+++ G-c- G-c- G-C +++ G-c- G-c-
G+c,++ G+c,+ G^c + G + c, ++ G + c, + G ^ c +
麦雑 G b,- 5.1 G+b,+ 4.6 G+b,++ 4.4-4.6 McMug G b,-5.1 G + b, + 4.6 G + b, ++ 4.4-4.6
G-b,++++ G-b,++ G-b,^  G-b, ++++ G-b, ++ G-b, ^
G-c,+++ G-c- G-c, +++ G-c-
G+C,-H- G+c,+ G + C, -H- G + c, +
G+b,- 5.4 G+b,+++ 5.4 G+b,++ 4Λ-4Λ G + b,-5.4 G + b, +++ 5.4 G + b, ++ 4Λ-4Λ
G-b,++++ G-b,+ G-b,++ G-b, ++++ G-b, + G-b, ++
G-c,+++ G^- G-C - G-c, +++ G ^-G-C-
G+C++ G+c+ G+c- 麦絲 G b,- 5.8 G+b, - 4.8 G+b,+++ 4.1 G + C ++ G + c + G + c- Max G b,-5.8 G + b,-4.8 G + b, +++ 4.1
G-b,++++ G-b,++ G-b,++  G-b, ++++ G-b, ++ G-b, ++
G-c,+++ G-c- G-c- G-c, +++ G-c- G-c-
G ^++ G+t,+ G+a+ G ^ ++ G + t, + G + a +
G+b,- 6.4 G+b,+ 4.4 G+b,+++ 4.1 G + b,-6.4 G + b, + 4.4 G + b, +++ 4.1
G-b, +++ G-b,++ G-b,+ G-b, +++ G-b, ++ G-b, +
G-c,+++ G-c- G-c, +++ G-c-
G+c,++ G+c+ G+c+ G + c, ++ G + c + G + c +
G+b,- 6.8 5.4 G+b,+++ 4.4 G + b,-6.8 5.4 G + b, +++ 4.4
G-b,++++ G-b,+ G-b,++ G-b, ++++ G-b, + G-b, ++
G-C-H- - G-C- &c,- G-C-H--G-C- & c,-
G+c,++ G+c- G+c + G + c, ++ G + c- G + c +
G+b,- 12 G+b,++ 5.4 G+b, ++ 4.1 G + b,-12 G + b, ++ 5.4 G + b, ++ 4.1
G-b,++++ G-b,+ G-b,++ G-b, ++++ G-b, + G-b, ++
G-c,+++ G-c,- H- G-c, +++ G-c,-H-
GHhC- G+ - 结论 GHhC- G +-Conclusion
体外实验中, 本发明药剂 pH值为 5.4-7.2时对革兰氏阳性杵菌 生长的刺激作用较强。 实验实例 6  In vitro experiments, the agent of the present invention has a strong stimulating effect on the growth of Gram-positive pestles at pH 5.4-7.2. Experimental Example 6
典型病例研究 1 Typical case study 1
蒋 XX,, 女性 30岁。 白带鱼腥样臭味伴有外阴瘙痒 2年, 被本 发明人检查诊断为 "细菌性阴道病" 并阴道内给予 pH值为 5.0、 含 12%乳糖的药剂每次 3 毫升、 每日一次、 连续三天治疗, 其阴道分 泌物 pH值由 5.4降至 4.6 , 涂片镜检仍以革兰氏阴性杆菌为主, 另 有较多阳性球菌和阳性杵菌。 遂改用 pH值为 5.0、含 12%麦芽糖的 本发明药剂 3ml, 10小时后患者阴道分泌物 pH值降低至 3.8, 减 量至含 12%麦芽糖的本发明药剂 2亳升、 每日一次, 可使阴道拭子 pH值维持在正常水平( pH<4.6 )。 后来该患者病情又多次于月经 后复发, 阴道内给予含 12%麦芽糖的本发明药剂治疗, 均可使其月 经后的异常阴道菌群和阴道酸度恢复正常。 实验实例 7 实验动物研究: 本发明药剂对恒河猴阴道菌群的影响 实验方法: Jiang XX, female, 30 years old. The fishy smell of leucorrhea accompanied by pruritus vulvae for 2 years was examined and diagnosed as "bacterial vaginosis" by the present inventors and administered vaginal pH 5.0, 12% lactose containing 3 ml each time, once a day, For three consecutive days of treatment, the pH value of vaginal secretions decreased from 5.4 to 4.6. Smear microscopy was still dominated by Gram-negative bacilli, and there were more positive cocci and positive pestles. Then use pH 5.0 and 12% maltose. 3ml of the agent of the present invention, the pH value of the vaginal secretion of the patient is reduced to 3.8 after 10 hours, and the amount of the agent of the present invention containing 12% maltose is reduced to 2 liters, once a day, so that the pH value of the vaginal swab can be maintained at a normal level (pH <4.6). Later, the patient's condition relapsed many times after menstruation, and the vaginal administration of the agent of the present invention containing 12% maltose could restore the abnormal vaginal flora and vaginal acidity after menstruation. Experimental example 7 Experimental animal research: Effect of the agent of the present invention on the vaginal flora of rhesus monkeys Experimental method:
( 1 ) 恒河猴的筛选: 取 10只恒河猴的阴道拭子, 测 pH值并 做菌群涂片染色、 镜检观察, 其中的 8只猴子阴道拭子卩11值>4.6 , 菌群以革兰氏阴性杆菌、 阴性球菌等为主, 阳性杆菌极少, 类似于人 类细菌性阴道病的菌群; 其中的两只猴子阴道拭子 pH值<4.6 , 菌群 以阳性杆菌为主, 类似于人类正常阴道菌群类型。  (1) Screening of rhesus monkeys: Take 10 vaginal swabs of rhesus monkeys, measure the pH value and perform microbiological staining and microscopic observation. Among them, 8 monkey vaginal swabs have a 卩 11 value of> 4.6, bacteria The main group is Gram-negative bacilli and negative cocci, and there are very few positive bacilli, similar to the flora of human bacterial vaginosis. Two monkey vaginal swabs have a pH value of <4.6, and the main groups are positive bacilli. It is similar to the normal type of human vaginal flora.
( 2 ) 阴道菌群为人类细菌性阴道病类型的恒河猴 8只, 排除 处于月经期的 3只, 余 5只为本实验对象。  (2) The vaginal flora was 8 rhesus monkeys of human bacterial vaginosis type. 3 menses were excluded, and the remaining 5 were subjects.
( 3 ) 药剂:为含 12%蔗糖、 1%酵母浸出物、 1.6%黄原胶、 pH值为 5.1的本发明药剂。  (3) Medicament: It is a medicament of the present invention containing 12% sucrose, 1% yeast extract, 1.6% xanthan gum, and a pH value of 5.1.
( 4 ) 给药方法: 上述本发明药剂 1亳升、 阴道内给药、 每曰 两次; 当阴道 pH值降至 4.6以下、 阴道菌群转变为以革兰氏阳性杆 菌为主时减量或停药,实验中 5只猴子中 1只给了一次药、 2只给了 两次药、 2只给了 3次药。  (4) Method of administration: 1 liter of the above-mentioned agent of the present invention, intravaginal administration, twice a day; when the vaginal pH value drops below 4.6, the vaginal flora changes to Gram-positive bacteria Or the drug was discontinued. In the experiment, one of the five monkeys was given once, two were given twice, and two were given three times.
( 5 ) 结果观察: 每次给药前取阴道拭子, 测 pH值并做涂片 染色、 镜检观察恒河猴阴道菌群; 实验结果: 用药后 5只猴子的阴道 pH值均降至 3.8-4.1 , 阴道菌群全部转 变为以革兰氏阳性杆菌为主,显示本发明药剂在体内对革兰氏阳性杵 菌生长和产酸有很强的刺激作用。 本发明与背景技术相比较的优越性: (5) Observation of results: Take vaginal swabs before each administration, measure pH and do smear staining, microscopic examination to observe the vaginal flora of rhesus monkeys; experimental results: After administration, the vaginal pH value of the five monkeys decreased to 3.8-4.1, and all the vaginal flora changed to Gram-positive bacilli, indicating that the agent of the present invention has a significant effect on the growth and acid production of Gram-positive pestles in vivo. Strong stimulating effect. Advantages of the present invention compared with the background art:
与抗菌治疗比较:  Compared with antibacterial treatment:
抗菌药物是从病原学观点出发, 采用杀菌或抑菌的方法来控制 过度生长并引起病理反应的异常细菌。 这种途径存在以下主要弊端: ( 1 )反复使用抗菌药屋后细菌会产生耐药性, 使疗效下降甚至无 效; ( 2 )抗菌治疗易继发耐药菌等的感染; ( 3 )抗菌药物有一定 的过敏与皮肤阴道等不良反应发生率。 以乳酸、 乙酸以及其它选择性 抑菌剂为活性成分的药剂, 如专利申请 GB2112285A 与 EP-A- 0257007公开的说明书所述药剂,对病菌抑制作用强而对乳酸杆菌无 明显抑菌作用, 可能间接有利于阴道中乳酸軒菌的生长。但这些药剂 本身不能直接、显著地促进乳酸杆菌生长, 其改善阴道酸度的作用也 较为短暂,阴道中的生理性苹兰氏阳性杆菌实际上很难恢复为优势菌 群。  Antibacterials are germicidal or bacteriostatic methods used to control abnormal bacteria that overgrow and cause pathological reactions from an etiological point of view. This approach has the following main disadvantages: (1) bacteria will develop drug resistance after repeated use of antibacterial drugstores, which will reduce the efficacy or even be ineffective; (2) antibacterial treatment is prone to secondary infections such as resistant bacteria; (3) antibacterial drugs There is a certain incidence of allergies and adverse reactions such as skin and vagina. Agents using lactic acid, acetic acid, and other selective bacteriostatic agents as active ingredients, such as those described in the specifications disclosed in patent applications GB2112285A and EP-A-0257007, have strong inhibitory effects on pathogens but have no obvious antibacterial effect on lactic acid bacteria. Indirectly beneficial to the growth of Lactobacillus in the vagina. However, these agents themselves cannot directly and significantly promote the growth of lactobacillus, and their effect of improving vaginal acidity is relatively short. It is actually difficult for the physiological Pinglan-positive bacteria in the vagina to recover to the dominant flora.
本发明药剂刺激阴道革兰氏阳性杆菌生长、增强阴道酸度, 通过 革兰氏阳性杆菌的生长和产酸这一间接机制对革兰氏阴性杵菌、球菌 和革兰氏阳性球菌等起抑制作用。因而本发明技术和药剂实质上是强 化阴道的生理性抗病机制,并从根本上避免和克服了抗菌治疗破坏阴 道正常菌群的弊端, 具明显优越性。  The agent of the invention stimulates the growth of vaginal Gram-positive bacilli and enhances the vaginal acidity, and inhibits Gram-negative pestles, cocci and Gram-positive cocci through the indirect mechanism of growth and acid production of Gram-positive bacilli . Therefore, the technology and medicament of the present invention substantially strengthen the physiological anti-disease mechanism of the vagina, and fundamentally avoid and overcome the disadvantages of antibacterial treatment to destroy the normal flora of the vagina, which has obvious advantages.
与乳酸杆菌制剂比较:  Compared with Lactobacillus preparations:
首先, 对比较重的阴道菌群失调如典型的细菌性阴道病例, 乳酸 杆菌制剂的疗效不稳定;其次,乳杆菌制剂的生产、保存有一定困难, 成本较高。 本发明制剂生产成本低、 有效期长, 显著优于乳酸杵菌制 剂; 且通过改善阴道局部微生境条件、促进患者阴道内固有的阳性杆 菌生长, 较直接补充外源性乳酸杆菌更好。 药剂实施例 实施例 1: First, for relatively severe vaginal flora disorders such as typical bacterial vaginal cases, the efficacy of lactobacillus preparations is unstable; second, the production and storage of lactobacillus preparations are difficult and costly. The preparation of the invention has low production cost, long validity period, and is significantly better than the lactobacillus lactis preparation. By improving local vaginal microhabitat conditions and promoting the growth of inherent positive bacilli in the patient's vagina, it is better than directly supplementing exogenous lactobacillus. Example of medicament Example 1:
将 2.5克蔗糖与 2.0克黄原胶混匀, 加入部分蒸餾水并搅拌, 使糖组分溶解、黄原胶溶胀呈均勾粘性胶状;加入适量乳酸调溶液的 pH至 5.0 , 再次加入蒸餾水至总体积 100ml ; 所得溶液用间歇灭菌 法灭菌。 实施例 2 按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂。 其中调 pH用 0.5N的氢氧化钠溶液。  Mix 2.5 grams of sucrose with 2.0 grams of xanthan gum, add a portion of distilled water and stir to dissolve the sugar components, and the xanthan gum will swell to a uniform viscosity; add an appropriate amount of lactic acid to adjust the pH of the solution to 5.0, and then add distilled water to The total volume is 100 ml; the resulting solution is sterilized by batch sterilization. Example 2 The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1. The pH was adjusted with 0.5N sodium hydroxide solution.
蔗糖 17.0% ( W/V )  Sucrose 17.0% (W / V)
酵母浸出粉 1.0% ( W/V )  Yeast Extraction Powder 1.0% (W / V)
黄原胶 1.5% ( W/V )  Xanthan gum 1.5% (W / V)
蒸犓水 足量  Steamed coriander water
pH 7.2 实施例 3:  pH 7.2 Example 3:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1:
蔗糖 12.0% ( W/V )  Sucrose 12.0% (W / V)
酵母浸出粉 1.0%( /V)  Yeast extract 1.0% (/ V)
黄原胶 1.0%(W/V)  Xanthan Gum 1.0% (W / V)
蒸馏水 足量  Distilled water
pH 4.1 实施例 4: pH 4.1 Example 4:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1:
蔗糖 4.0%(W/V)  Sucrose 4.0% (W / V)
麦芽糖 5.0%(W/V)  Maltose 5.0% (W / V)
果糖 2.0(W/V)  Fructose 2.0 (W / V)
組氨酸 lOOppm  Histidine 100 ppm
甲硫氨酸 50.0ppm  Methionine 50.0ppm
核黄素 0.2ppm  Riboflavin 0.2ppm
硫胺素 0.2ppm  Thiamine 0.2ppm
烟酸 0.2ppm  Niacin 0.2ppm
泛酸钙 0.2ppm  Calcium pantothenate 0.2ppm
黄原胶 1.5%(W/V)  Xanthan gum 1.5% (W / V)
蒸馏水 足量  Distilled water
PH 6.4 实施例 5:  PH 6.4 Example 5:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1:
麦芽糖 2.5%(W/V)  Maltose 2.5% (W / V)
黄原胶 1.6%(W/V)  Xanthan gum 1.6% (W / V)
蒸馏水 足量  Distilled water
pH 6.8  pH 6.8
实施例 6: Example 6:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂: 麦芽糖 17.0%(W/V) The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1: Maltose 17.0% (W / V)
黄原胶 1.6%(W/V)  Xanthan gum 1.6% (W / V)
酵母浸出粉 1.0%(W/V)  Yeast Extraction Powder 1.0% (W / V)
蒸馏水 足量  Distilled water
pH 5.4 实施例 7:  pH 5.4 Example 7:
按下述配比称取原料, 基本按实施例 的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of the example:
麦芽糖 13.0%(W/V)  Maltose 13.0% (W / V)
酵母浸出粉 1.0%(W/V)  Yeast Extraction Powder 1.0% (W / V)
黄原胶 1.6%(W/V)  Xanthan gum 1.6% (W / V)
蒸馏水 足量  Distilled water
PH 6.4 实施例 8:  PH 6.4 Example 8:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1:
麦芽糖 10.0%(W/V)  Maltose 10.0% (W / V)
葡萄糖 2.0%(W/V)  Glucose 2.0% (W / V)
酵母浸出粉 1.0%(W/V)  Yeast Extraction Powder 1.0% (W / V)
黄原胶 1.6%(W/V)  Xanthan gum 1.6% (W / V)
蒸鐳水 足量  Steamed radium water
pH 4.8 实施例 9:  pH 4.8 Example 9:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂: 蔗糖 12.0 % ( W/V ) The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1: Sucrose 12.0% (W / V)
葡萄糖 1.0 % ( W/V )  Glucose 1.0% (W / V)
酵母浸出粉 0.5 % ( W/V )  Yeast extract 0.5% (W / V)
黄原胶 1.7 % ( W/V )  Xanthan Gum 1.7% (W / V)
蒸镏水 足量 Steamed coriander water
H 5.6 实施例 10:  H 5.6 Example 10:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1:
蔗糖 10.0 % ( W/V )  Sucrose 10.0% (W / V)
1.0 % ( W/V )  1.0% (W / V)
组氨酸 100 ppm  Histidine 100 ppm
甲破氨酸 50.0 ppm  Methionine 50.0 ppm
核黄素 0.2 ppm  Riboflavin 0.2 ppm
硫胺素 0.2 ppm  Thiamine 0.2 ppm
烟酸 0.2 ppm  Niacin 0.2 ppm
泛 酸钙 0.2 ppm  Calcium pantothenate 0.2 ppm
黄 原 胶 1.8 % ( W V )  Xanthan gum 1.8% (W V)
蒸馏水 足量  Distilled water
pH 6.5 实施例 11:  pH 6.5 Example 11:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1:
麦芽糖 10.0 % ( W V )  Maltose 10.0% (W V)
酮康唑 2.0 % ( W/V )  Ketoconazole 2.0% (W / V)
酵母浸出物 1.0 % ( W/V ) 黄原胶 1.50 % ( W/V ) Yeast extract 1.0% (W / V) Xanthan gum 1.50% (W / V)
蒸餾水 足量 Distilled water
H 6.0 实施例 12:  H 6.0 Example 12:
按下述配比称取原料, 基本按实施例 1的方法制备了 100ml药 剂:  The raw materials were weighed according to the following proportions, and 100 ml of the medicine was basically prepared according to the method of Example 1:
麦芽糖 9.0 % ( W/V )  Maltose 9.0% (W / V)
多粘菌素 E 0.5 % ( W/V )  Polymyxin E 0.5% (W / V)
酵母浸出粉 1.0 % ( W/V )  Yeast extract 1.0% (W / V)
黄原胶 2.2 % ( W/V )  Xanthan gum 2.2% (W / V)
蒸餾水 足量  Distilled water
pH 6.3  pH 6.3
本发明的药剂成分简单, 易于制备, 耗资低。 The medicinal composition of the invention is simple, easy to prepare, and low in cost.
参考文献 references
1) German-M , et al : Genital flora in pregnancy and its association with intrauterine growth retardation · J - Clin ― Microbiol · 1994 Sep: 32(9): 2162 - 8.  1) German-M, et al: Genital flora in pregnancy and its association with intrauterine growth retardation · J-Clin ― Microbiol · 1994 Sep: 32 (9): 2162-8.
2) McDonald-HM, et al : Vaginal infection and preterm labour · Br-J-Obstet-Gynaecol . 1991 May; 98(5): 427-35. 2) McDonald-HM, et al: Vaginal infection and preterm labour · Br-J-Obstet-Gynaecol. 1991 May; 98 (5): 427-35.
3) Eschenbach.DA, Clin.Infect.Dis. 1993.16(Suppl.4):S282-7. 3) Eschenbach.DA, Clin.Infect.Dis. 1993.16 (Suppl.4): S282-7.
4) Thomason JL - Bacterial vaginosis: current review with indications for asymptomatic therapy. Am J Obstet Gynecol .1991; 165: 1210 .  4) Thomason JL-Bacterial vaginosis: current review with indications for asymptomatic therapy. Am J Obstet Gynecol. 1991; 165: 1210.
5) Stein-GE, et al: Placebo-controlled trial of intravaginal clindamycin 2% cream for the treatment of bacterial .  5) Stein-GE, et al: Placebo-controlled trial of intravaginal clindamycin 2% cream for the treatment of bacterial.
vaginosis - Ann-Pharmacother. 1993 Nov , 27(11): 1343-5. vaginosis-Ann-Pharmacother. 1993 Nov, 27 (11): 1343-5.
6) Hillier-SL, et al: Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis . Obstet-Gynecol. 1993 Jim; 81(6): 963-7.  6) Hillier-SL, et al: Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet-Gynecol. 1993 Jim; 81 (6): 963-7.
7) Hoster-E, et al: Treatment of bacterial vaginosis in pregnancy with a lactate gel. Scand-J-Infect-Dis. 1990; 22(5):625-6.  7) Hoster-E, et al: Treatment of bacterial vaginosis in pregnancy with a lactate gel. Scand-J-Infect-Dis. 1990; 22 (5): 625-6.
8) Boeke-AJ, et al: Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial. Genitourin-Med. 1993 Oct; 69(5): 388-92. 8) Boeke-AJ, et al: Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial. Genitourin-Med. 1993 Oct; 69 (5): 388-92.
9) Hallen-A, et al: Treatment of bacterial vaginosis with lactobacilli. Sex-Transm-Dis. 1992 May-Jun; 19(3): 146-8. 9) Hallen-A, et al: Treatment of bacterial vaginosis with lactobacilli. Sex-Transm-Dis. 1992 May-Jun; 19 (3): 146-8.
10) Hughes- VL, et al: Microbiologic characteristics of lactobacillus products used for colonization of the vagina. Obstet-Gynecol. 1990 Feb; 75(2): 244-8 .  10) Hughes- VL, et al: Microbiologic characteristics of lactobacillus products used for colonization of the vagina. Obstet-Gynecol. 1990 Feb; 75 (2): 244-8.

Claims

权 利 要 求 Rights request
1. 一种剌激阴道革兰氏阳性杆菌生长、 增强阴道酸度的水基药剂, 其特征在于, 按药剂总体积计, 其含有总量为 2.5-17%(W/V)的蔗糖 或 /和麦芽糖; 还可含有一种或多种选自下组的糖: 葡萄糖、 果糖、 半乳糖、 甘露糖、 乳糖、 乳果糖、 海藻糖、 纤维二糖、 蜜二糖、 棉子 糖、 麦芽寡糖、 异麦芽寡糖、 低聚果糖、 糊精、 淀粉和糖原; 药剂 pH值范围为 4.1-7.2, 可用药物可以接受的酸或碱来调节; 可选择性 地含有可药用的粘性基质;还可选择性地含有有效量的抗真菌药物和 /或抗细菌药物。 1. A water-based agent that stimulates the growth of vaginal Gram-positive bacilli and enhances vaginal acidity, characterized in that it contains 2.5-17% (W / V) sucrose or / And maltose; may also contain one or more sugars selected from the group consisting of glucose, fructose, galactose, mannose, lactose, lactulose, trehalose, cellobiose, melibiose, raffinose, malto-oligosaccharide Sugars, isomalt oligosaccharides, fructooligosaccharides, dextrin, starch and glycogen; the pH range of the agent is 4.1-7.2, which can be adjusted with pharmaceutically acceptable acids or bases; optionally contains a pharmaceutically acceptable viscous matrix It may also optionally contain an effective amount of an antifungal drug and / or an antibacterial drug.
2. 根据权利要求 1的药剂, 其中糖含量为 8-14%(W/V)。  The medicament according to claim 1, wherein the sugar content is 8-14% (W / V).
3. 根据权利要求 2的药剂, 其中糖含量为 10-12%(W/V)。  3. The medicament according to claim 2, wherein the sugar content is 10-12% (W / V).
4. 根据权利要求 1的药剂, 其中当其它种类的双糖与蔗糖或 /和麦芽 糖混合使用时, 其含量不大于 [17-蔗糖或 /和麦芽糖含量)%(\¥/\ 。  The medicament according to claim 1, wherein when other kinds of disaccharides are used in combination with sucrose or / and maltose, the content thereof is not more than [17-sucrose or / and maltose content)% (\ ¥ / \).
5. 根据权利要求 1的药剂, 其中当己糖与蔗糖或 /和麦芽糖混合使用 时, 己糖含量低于 0.42 X (17-所用双糖量)%(\¥/¥)。  5. The medicament according to claim 1, wherein when hexose is used in combination with sucrose or / and maltose, the hexose content is less than 0.42 X (17-amount of disaccharide used)% (\ ¥ / ¥).
6. 根据权利要求 1的药剂, 其中 pH值范围为 4.5-6.5。  6. The medicament according to claim 1, wherein the pH value ranges from 4.5 to 6.5.
7. 根据权利要求 1的药剂, 其中含有 1.0-2.2% ( W/V )的黄原胶。  7. The medicament according to claim 1, which contains 1.0-2.2% (W / V) xanthan gum.
8. 根据权利要求 1的药剂, 其中不含粘性基质, 呈可以浸泡阴道塞 的真溶液形式。  8. The medicament according to claim 1, which does not contain a viscous matrix and is in the form of a true solution capable of soaking a vaginal plug.
9. 根据权利要求 1的药剂, 其中还含有有效量的抗真菌药物。  9. The medicament according to claim 1, further comprising an effective amount of an antifungal drug.
10.根据权利要求 9的药剂, 其中的抗真菌药物为酮康唑、 曲康唑、 伊曲康唑和氟康唑。  The medicament according to claim 9, wherein the antifungal drug is ketoconazole, itraconazole, itraconazole, and fluconazole.
11.根据权利要求 1的药剂, 其中还含有有效量的选择性抗革兰氏阴 性细菌的药物。  The medicament according to claim 1, which further contains an effective amount of a drug which is selective against Gram-negative bacteria.
12.根据权利要求 11 的药剂, 其中的抗细菌药物为灭滴灵、 多粘菌 素、 氨曲南。  The medicament according to claim 11, wherein the antibacterial drug is metronidazole, polymyxin, aztreonam.
13.蔗糖或麦芽糖作为活性成分在制备剌激阴道革兰氏阳性杆菌生 长、 增强阴道酸度的药剂中的用途。 13. Sucrose or maltose as active ingredients in the preparation of stimulated vaginal Gram-positive bacteria Use in long, vaginal acidity-enhancing medicaments.
14.根据权利要求 13的用途,其中所述药剂是用于治疗阴道革兰氏阳 性杆菌减少、 阴道酸度减弱的药物。  The use according to claim 13, wherein the medicament is a medicament for treating a decrease in vaginal Gram-positive bacilli and a decrease in vaginal acidity.
15.根据权利要求 13的用途,其中所述药剂是用于治疗伴有阳性杆菌 减少的阴道炎、 阴道菌群失调的药物。  The use according to claim 13, wherein the medicament is a medicament for treating vaginitis and vaginal flora disorders accompanied by reduction of positive bacilli.
16.根据权利要求 13的用途,其中所述药剂是用于治疗细菌性阴道病 的药物。  16. The use according to claim 13, wherein the medicament is a medicament for the treatment of bacterial vaginosis.
17.—种刺激阴道革兰氏阳性杵菌生长、 增强阴道酸度的方法, 其中 给予有此需要的主体以治疗有效量的权利要求 1-12任一项的药剂。  17. A method for stimulating the growth of vaginal Gram-positive pestles and enhancing vaginal acidity, wherein a subject in need thereof is administered a therapeutically effective amount of the medicament of any one of claims 1-12.
18.—种治疗阴道革兰氏阳性杆菌减少和阴道酸度减弱的方法, 其中 给予有此需要的主体以治疗有效量的权利要求 1-12任一项的药剂。  18. A method of treating a decrease in vaginal Gram-positive bacilli and a decrease in vaginal acidity, wherein a subject in need thereof is administered a therapeutically effective amount of a medicament according to any one of claims 1-12.
19.一种治疗伴有革兰氏阳性杵菌减少的阴道炎、 阴道菌群失调的方 法, 其中给予有此需要的主体以治疗有效量的权利要求 1-12任一项 的药剂。  A method for treating vaginitis and vaginal flora disorders accompanied by reduction of Gram-positive pestles, wherein a subject in need thereof is administered a therapeutically effective amount of the medicament according to any one of claims 1-12.
20.—种治疗细菌性阴道病的方法, 其中给予有此需要的主体以治疗 有效量的权利要求 1-12任一项的药剂。  20. A method of treating bacterial vaginosis, wherein a subject in need thereof is administered a therapeutically effective amount of a medicament according to any one of claims 1-12.
PCT/CN1998/000277 1997-11-24 1998-11-24 Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof WO1999026635A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69831609T DE69831609T2 (en) 1997-11-24 1998-11-24 PHARMACEUTICAL COMPOSITION FOR STIMULATING THE GROWTH OF GRAM-POSITIVE BACILS AND FOR INCREASING THE AZIDITY OF VAGINA AND ITS USE
AU12230/99A AU1223099A (en) 1997-11-24 1998-11-24 Pharmaceutical formulation for stimulating the growth of gram-positive bacil li and increasing the acidity in vagina and the use thereof
AT98955312T ATE304362T1 (en) 1997-11-24 1998-11-24 PHARMACEUTICAL COMPOSITION FOR STIMULATING THE GROWTH OF GRAM-POSITIVE BACILLAS AND INCREASE THE ACIDITY OF THE VAGINA AND THEIR USE
EP98955312A EP1072268B1 (en) 1997-11-24 1998-11-24 Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof
US09/577,858 US6632796B1 (en) 1997-11-24 2000-05-24 Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN97122790.X 1997-11-24
CN97122790 1997-11-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/577,858 Continuation US6632796B1 (en) 1997-11-24 2000-05-24 Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof

Publications (1)

Publication Number Publication Date
WO1999026635A1 true WO1999026635A1 (en) 1999-06-03

Family

ID=5176887

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN1998/000277 WO1999026635A1 (en) 1997-11-24 1998-11-24 Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof
PCT/CN1998/000278 WO1999026636A1 (en) 1997-11-24 1998-11-24 Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN1998/000278 WO1999026636A1 (en) 1997-11-24 1998-11-24 Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof

Country Status (7)

Country Link
US (2) US6440949B1 (en)
EP (2) EP1072268B1 (en)
CN (2) CN1120000C (en)
AT (2) ATE304362T1 (en)
AU (2) AU1223199A (en)
DE (2) DE69831878D1 (en)
WO (2) WO1999026635A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197231A1 (en) * 2000-10-11 2002-04-17 Uni-Charm Corporation Absorbent article for controlling normal flora of the skin
WO2006114061A1 (en) * 2005-04-27 2006-11-02 Shenzhen Phlora Biotechnology Limited A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vaginal
WO2015135470A1 (en) * 2014-03-13 2015-09-17 曾忠铭 Composition for vagina and use of the composition
CN109771434A (en) * 2019-03-07 2019-05-21 江西鼎中科技有限公司 A kind of sucrose that treating vaginitis and xylo-oligosaccharide gel
CN112451472A (en) * 2020-11-27 2021-03-09 江苏威克斯医疗科技有限公司 Composition for regulating vaginal microecology and preparation method thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306141B1 (en) * 1999-05-17 2001-05-30 Giampiero Valletta COMPOSITION FOR THE TREATMENT OF UREMIC ITCHING AND OF DEPRURED FORMS NOT RELATED TO ORGANIC INJURIES.
US6964949B2 (en) * 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
NZ515869A (en) 2001-11-30 2003-09-26 Med Chem Ingredients Ltd Compositions and methods for animal treatment comprising gluco- and isomalto- oligosaccharides
US6589216B1 (en) 2002-02-20 2003-07-08 Abbott Research Group, Inc. Vaginal douches, vaginal douche applicators and methods of vaginal douching
US7270653B2 (en) 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US8118789B2 (en) 2002-02-20 2012-02-21 Abbott Research Group, Inc. Deodorizer devices and systems for controlling perspiration-related body odor
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
BRPI0411429A (en) * 2003-06-13 2006-07-25 Idh Holding Aps treatment of symptoms associated with bacterial vaginosis
US8309103B2 (en) * 2004-01-22 2012-11-13 Alparis, S.A. De C.V. Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US20060223765A1 (en) * 2005-03-30 2006-10-05 Kimberly-Clark Worldwide, Inc. Method for inhibiting and/or treating vaginal infection
US7786176B2 (en) 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
US7801502B2 (en) * 2006-12-18 2010-09-21 Aai Corporation Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems
SG171444A1 (en) 2009-01-23 2011-07-28 Acraf Controlled release pharmaceutical or food formulation and process for its preparation
KR101133723B1 (en) * 2009-10-19 2012-04-09 최원석 Composition comprising salt and sugar for protecting and treating vaginosis disease and the use thereof
US8409628B2 (en) 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
EP2489408A1 (en) 2011-01-13 2012-08-22 Michael Tchirikov Amino acid compound and use of same for treating intrauterine growth restriction (IUGR) and for parenteral feeding of extremely premature infants
CN103110973A (en) * 2013-01-24 2013-05-22 量子高科(中国)生物股份有限公司 Method for protecting reproductive tract microecological health balance
CN104825946A (en) * 2015-04-10 2015-08-12 付秀花 Vagina cleaning lotion and preparation method thereof
PT3324938T (en) * 2015-07-20 2021-09-21 Trilogic Pharma Llc Topical formulations and treatments
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
EP3442501A1 (en) 2016-04-15 2019-02-20 Fairhaven Health, LLC Compositions and methods for maintaining or enhancing homeostasis or function of female lower reproductive tract
GB202018068D0 (en) 2020-11-17 2020-12-30 Ucl Business Ltd Pharmaceutical composition
EP4324465A1 (en) * 2022-08-15 2024-02-21 Gedea Biotech AB Compounds for use in the treatment of a microbial infection in the urogenital system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860707A (en) * 1972-07-18 1975-01-14 Philips Corp Method of treating vaginitis
GB2112285A (en) * 1981-12-21 1983-07-20 Serono Ist Farm Composition for intimate feminine hygiene
WO1994002148A1 (en) * 1992-07-22 1994-02-03 Vepex Kft. Novel bioactive compositions, preparation and use thereof
WO1994003502A1 (en) * 1992-08-04 1994-02-17 Istituto Ricerca Francesco Angelini S.P.A. Glycogen polysaccharides
CN1104502A (en) * 1993-12-29 1995-07-05 昆明宏达实业有限总公司 External-use medicine for gynecopathy
US5518733A (en) * 1991-06-27 1996-05-21 Bioeurope Cosmetic compositions containing oligosaccharides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190770B1 (en) * 1985-02-08 1992-10-07 Daicel Chemical Industries, Ltd. Fermentation to d-lactic acid
JPS61227777A (en) * 1985-04-02 1986-10-09 Showa Sangyo Kk Agent for activating growth of bifidus bacteria
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
SE8603338D0 (en) * 1986-08-07 1986-08-07 Bjorn Andersch METHOD FOR TREATING CONDITIONS IN SLIDANE
US4837154A (en) * 1987-01-14 1989-06-06 Wisconsin Alumni Research Foundation Selective growth medium for isolation of Mobiluncus from vaginal fluid
DK505488D0 (en) * 1987-12-21 1988-09-09 Bar Shalom Daniel MEDIUM AND USE OF SAME
US5211971A (en) * 1989-10-23 1993-05-18 Unilever Patent Holdings B.V. Lactic acid bacteria cultures supported on an expanded cereal for preparing flavor or aroma material
DK0564586T3 (en) * 1990-12-21 2002-07-15 Felice Bombart Aqueous vaginal rinses and related procedures
US5573765A (en) * 1991-02-19 1996-11-12 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
SE9200199L (en) * 1992-01-24 1993-07-25 Rune Soeremark PHARMACEUTICAL COMPOSITION AND ITS USE
DE19503423A1 (en) * 1995-02-03 1996-08-08 Beiersdorf Ag Antiadhesive agents
EP0881905A1 (en) * 1996-02-14 1998-12-09 The Procter & Gamble Company Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860707A (en) * 1972-07-18 1975-01-14 Philips Corp Method of treating vaginitis
GB2112285A (en) * 1981-12-21 1983-07-20 Serono Ist Farm Composition for intimate feminine hygiene
US5518733A (en) * 1991-06-27 1996-05-21 Bioeurope Cosmetic compositions containing oligosaccharides
WO1994002148A1 (en) * 1992-07-22 1994-02-03 Vepex Kft. Novel bioactive compositions, preparation and use thereof
WO1994003502A1 (en) * 1992-08-04 1994-02-17 Istituto Ricerca Francesco Angelini S.P.A. Glycogen polysaccharides
CN1104502A (en) * 1993-12-29 1995-07-05 昆明宏达实业有限总公司 External-use medicine for gynecopathy

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197231A1 (en) * 2000-10-11 2002-04-17 Uni-Charm Corporation Absorbent article for controlling normal flora of the skin
US6706941B2 (en) 2000-10-11 2004-03-16 Uni-Charm Corporation Absorbent article for controlling normal flora of the skin
WO2006114061A1 (en) * 2005-04-27 2006-11-02 Shenzhen Phlora Biotechnology Limited A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vaginal
US8586549B2 (en) 2005-04-27 2013-11-19 Shenzhen Phlora Biotechnology Limited Composition and method for modulating and maintaining vaginal bacterial flora and vaginal acidity
WO2015135470A1 (en) * 2014-03-13 2015-09-17 曾忠铭 Composition for vagina and use of the composition
US20160375045A1 (en) * 2014-03-13 2016-12-29 Singapore Ze&Z International Pte. Ltd Vaginal composition and use thereof
US10869878B2 (en) 2014-03-13 2020-12-22 Singapore Ze&Z International Pte. Ltd Vaginal composition and use thereof
US11951116B2 (en) 2014-03-13 2024-04-09 Singapore Ze&Zinternational Pte. Ltd Vaginal composition and use thereof
CN109771434A (en) * 2019-03-07 2019-05-21 江西鼎中科技有限公司 A kind of sucrose that treating vaginitis and xylo-oligosaccharide gel
CN112451472A (en) * 2020-11-27 2021-03-09 江苏威克斯医疗科技有限公司 Composition for regulating vaginal microecology and preparation method thereof

Also Published As

Publication number Publication date
ATE304362T1 (en) 2005-09-15
EP1072268B1 (en) 2005-09-14
EP1072269B1 (en) 2005-10-12
AU1223199A (en) 1999-06-15
CN1120001C (en) 2003-09-03
EP1072269A4 (en) 2003-08-27
DE69831609D1 (en) 2005-10-20
DE69831878D1 (en) 2006-02-23
ATE306274T1 (en) 2005-10-15
WO1999026636A1 (en) 1999-06-03
CN1120000C (en) 2003-09-03
US6440949B1 (en) 2002-08-27
CN1271291A (en) 2000-10-25
CN1271290A (en) 2000-10-25
EP1072268A1 (en) 2001-01-31
DE69831609T2 (en) 2006-02-02
EP1072268A4 (en) 2003-09-03
AU1223099A (en) 1999-06-15
EP1072269A1 (en) 2001-01-31
US6632796B1 (en) 2003-10-14

Similar Documents

Publication Publication Date Title
WO1999026635A1 (en) Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof
US8586549B2 (en) Composition and method for modulating and maintaining vaginal bacterial flora and vaginal acidity
US11951116B2 (en) Vaginal composition and use thereof
EP3520785A1 (en) Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use
WO2011041938A1 (en) Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof
EP2343088A1 (en) Antimycotic and prebiotic pharmaceutical composition and a method for treating candidal vaginitis
WO2021160049A1 (en) Bacteriostatic composition, preparation method therefor and use thereof
US6964949B2 (en) Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
WO2004110461A1 (en) Treatment of symptoms associated with bacterial vaginosis
CN115919742A (en) Tinidazole suppository composition and preparation method and application thereof
US20040229822A1 (en) Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof
CN107837274A (en) A kind of purposes of diet fiber composition
JP2023549260A (en) Pharmaceutical composition for use in the prevention or treatment of conditions associated with reduced numbers of Lactobacillus in the vagina
CN1240136A (en) Medicine for promoting growth of vagina gram-positive bacillus and increasing vagina acidity and usage thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98809508.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09577858

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998955312

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998955312

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1998955312

Country of ref document: EP